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ABSTRACT
Equilibrative nucleoside transporter 1 (ENT1) regulates the bi-directional transfer of
hydrophilic nucleosides, such as adenosine, across the plasma membrane. Mice lacking
ENT1 developed calcified lesions resembling diffuse idiopathic skeletal hyperostosis
(DISH) in humans. By 12 months of age, ENT1-/- mice exhibit spine stiffness, hind limb
dysfunction, and paralysis. Histological examination of ENT1-/- mice revealed irregular
accumulations of eosinophilic material in paraspinal ligaments and entheses,
intervertebral discs, and sternocostal articulations. There was no evidence of
mineralization in appendicular joints or blood vessels. Analysis of intervertebral disc
tissues of 6 month old ENT1-/- and wild-type mice revealed reduced expression of
mineralization

inhibitors,

including

matrix

gla

protein

(Mgp),

ectonucleotide

pyrophosphatase/phosphodiesterase 1 (Enpp1), progressive ankylosis (Ank), and
osteopontin (Spp1). The expression of these genes was not altered in tissues which do not
exhibit ectopic mineralization. Thus, a reduction of proteins that normally prevent soft
tissue mineralization may induce the ectopic calcification of spinal tissues observed in
ENT1-/- mice.

Key words: biomineralization, adenosine, equilibrative nucleoside transporters,
intervertebral disc, soft connective tissue
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Never give up on something you cannot go a day without thinking about.
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Chapter 1

Introduction

1

1.1 Nucleobases, Nucleosides, and Nucleotides
Nucleobases, also known as nitrogenous bases, are nitrogen-containing
heterocyclic compounds present in DNA, RNA, nucleotides and nucleosides. Based on
their structure, nucleobases can be classified into one of two groups. Purine bases contain
two carbon-nitrogen rings, whereas pyrimidine bases contain one carbon-nitrogen ring
(1). There are five nucleobases: adenine, guanine, cytosine, thymine (DNA only) and
uracil (RNA only); adenine and guanine are purine bases and cytosine, thymine and
uracil are pyrimidine bases.
Nucleosides (adenosine, guanosine, cytidine, thymidine, uridine and inosine) are
pyrimidine or purine nitrogenous bases attached to a ribose or 2-deoxyribose ring of a
pentose sugar via a β-glycosidic bond (2) (Fig. 1.1). Nucleotides are nucleosides bound to
one or more phosphate groups that covalently attach to the ribose or 2-deoxyribose ring
of the pentose sugar (3).
Nucleosides are important biological molecules. These molecules form the
structural subunit of nucleic acids (DNA and RNA) and nucleotides (such as adenosine
triphosphate, ATP) that are important in biological processes like cellular replication and
energy supply (4). Nucleosides and nucleotides have been shown to serve as
neurotransmitters and neuromodulators (5,6), and play important roles in cell signaling
through cyclic adenosine monophosphate (cAMP) and adenosine (discussed in section
1.2).
Cytotoxic nucleoside analogues and nucleobases are also used as antiviral,
antiparasitic and anticancer agents, and induce toxicity by interacting with a large number

2

Figure 1.1: Chemical structures of physiological nucleosides. (modified from Young
et al., 2008)
Adenosine, inosine, and guanosine are purine nucleosides while cytidine, uridine, and
thymidine are pyrimidine nucleosides.

3

of intracellular targets (7-9). Cytotoxic nucleoside analogues compete with physiological
nucleosides as these molecules share common characteristics, including transport
mediated by membrane transporters, activation by intracellular processes that retain the
residues in the cell, and formation of the active derivatives (7) . These agents can exert
cytotoxic activity by direct incorporation into nucleic acids; by interfering with various
enzymes involved in the synthesis of nucleic acids; or by modifying the metabolism of
physiological nucleosides (7,8).

1.2 Adenosine
Adenosine is a purine nucleoside which plays a critical role in many different
processes. Adenosine has a well-established role as the building block for the important
energy molecule ATP, and is also required for nucleic acid synthesis. Free adenosine is
an important signaling molecule (10). It is recognized as a local regulator of tissue
function, especially when the available energy supply is unable to meet cellular energy
demands (11). In cases like this, adenosine is produced by the tissue under stress which
increases the energy supply (by vasodilation) and decreases the energy demand by acting
as a negative feedback regulator.
There has been an increasing interest in the role of purinergic signaling,
specifically that of adenosine, in the physiology and pathophysiology of musculoskeletal
tissues (12). Recent studies point to a critical role for purine metabolism in the regulation
of biomineralization in diseases associated with either insufficient or ectopic
mineralization (Fig. 1.2) (12-15). A study showed that mutations in the gene encoding

4

Pi

adenosine
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adenosine

ALPL

NT5E

PPi
AMP

Calcium Phosphate

ENPP1

adenosine

ATP

Ca

PPi

2+

signaling

ATP
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PPi

gene expression

MGP, SPP1

Figure 1.2: Schematic of pathways influencing biomineralization.
Adenosine can regulate cell behaviour and gene expression through cell surface
receptors. ATP is released into the extracellular fluid and subsequently metabolized by
cell-surface enzymes. Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1)
metabolizes ATP, and releases inorganic pyrophosphate (PPi), which inhibits
mineralization. Extracellular PPi levels are also regulated by progressive ankylosis
protein (ANK), a putative transporter that mediates PPi efflux. PPi is metabolized by
another cell surface enzyme, alkaline phosphatase (ALPL), which produces inorganic
phosphate (Pi), promoting mineralization. Pi and Ca2+ accumulate in matrix vesicles or on
extracellular matrix components resulting in the crystallization of calcium phosphate,
leading to formation of hydroxyapatite and thus, matrix calcification. In addition to the
regulation of biomineralization through changes in PPi levels or PPi:Pi ratio, cells express
and secrete proteins that can promote or inhibit calcification of the extracellular matrix.
These proteins include the mineralization inhibitors matrix Gla protein (MGP) and
osteopontin (SPP1).
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ENPP1 have been associated with a hypermineralization disorder known as idiopathic
infantile arterial calcification (13). ENPP1 is an ecto-enzyme responsible for the
hydrolysis of ATP to adenosine monophosphate (AMP), generating inorganic
pyrophosphate (PPi), which inhibits soft tissue calcification. Through characterization of
mice lacking ecto-5’-nucleotidase (Nt5e), Takedachi and colleagues demonstrated that
adenosine promotes osteoblast differentiation (12). The Nt5e gene encodes the CD73
cell-surface enzyme, which converts AMP to adenosine. Furthermore, it was found that
CD73-/- mice had significantly lower bone mineral content, and as a result reduced bone
volume and thickness, compared to wild-type controls (12). As demonstrated by St.
Hilarie et al., mutations in NT5E show a genetic association with symptomatic arterial
and joint calcifications in humans (14). All reported mutations in NT5E resulted in a nonfunctional CD73 enzyme. In addition, cultured fibroblasts from affected individuals
showed reduced expression of the NT5E mRNA and the CD73 protein, increased tissuenonspecific alkaline phosphatase (ALPL) enzyme activity, and consequently the
accumulation of calcium phosphate crystals (14).

ALPL is a cell-surface enzyme

responsible for hydrolyzing PPi to inorganic phosphate (Pi, which promotes calcification).
These studies suggest a possible link between adenosine metabolism and the regulation of
biomineralization.
1.2.1 Adenosine Bioactivity
Adenosine, released locally, mediates its physiological and pharmacological
actions via interactions with G protein-coupled receptors. Extracellular adenosine acts as
a ligand for purinergic cell surface adenosine receptors; there are four subtypes of these
receptors – A1, A2a, A2b, A3 – with specific tissue distribution, pharmacology, and

6

signaling mechanisms (16,17). The A1 and A3 receptors signal through an inhibitory G
protein (Gi), which inhibits cAMP production by adenylate cyclase. In contrast, the A2a
and A2b receptors signal through a stimulatory G protein (Gs), which increases cAMP
production (16,18). cAMP has been shown to induce abnormal calcification of vascular
smooth muscle cells via a mechanism involving reduction in extracellular PPi
accumulation (19).
Bone is a dynamic organ that undergoes continuous remodeling through a balance
of bone formation and bone resorption. Osteoblasts, which are bone forming cells,
synthesize new bone, while osteoclasts resorb bone (20,21). Recent studies have shown
that adenosine receptors are involved in osteoblast and osteoclast differentiation and
function. Studies demonstrated the presence of all four adenosine receptors in murine
bone marrow cell osteoclast precursors, and showed that receptors were up-regulated
during osteoclast differentiation (22). In the A1 receptor-knockout mouse, there was a
significant increase in bone density and volume due to compromised osteoclast-mediated
resorption ability (23). Furthermore, the presence of A1 receptor antagonists have been
shown to inhibit osteoclast formation (24). In contrast to the A1 receptor, activation of the
A2a receptor inhibits osteoclastogenesis; mice deficient in the A2a receptor show a
reduction in bone density (25). It has also been reported that the A2a receptor plays a role
in promoting the proliferation of mouse bone marrow-derived mesenchymal stem cells
and is up-regulated at later osteoblast differentiation stages (26,27), however the A2b
receptor is reported as the functionally dominant receptor involved in osteoblast
differentiation (28). Little is known about the role of the A3 receptor in musculoskeletal
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tissues, however the receptor is expressed on the surfaces of osteoblasts (29), and its
selective agonist increases primary osteoblast proliferation (30).
1.3 Nucleoside Transporters
As hydrophilic molecules, nucleosides and their analogues require specialized
glycoprotein transporters to cross the hydrophobic cellular membrane (4,8). Given the
importance of these molecules in intracellular nucleotide generation, as well as
extracellular signaling, the ability of cells to accumulate these molecules depends on their
efficient movement across membranes. In addition, cells incapable of de novo nucleoside
synthesis, such as enterocytes, bone marrow cells, and certain brain cells require
transporters to salvage nucleosides from the extracellular environment (4). In mammals,
nucleoside transport is carried out by seven transporters which are classified into two
distinct families based on their transport mechanism: the concentrative nucleoside
transporters (CNTs 1-3, also known as SLC28) and the equilibrative nucleoside
transporters (ENTs 1-4, also known as SLC29) (4,8,31).
1.3.1 Concentrative Nucleoside Transporters (CNTs)
CNTs are Na+-dependent symporters that move nucleosides and nucleobases
against a concentration gradient. The CNT family consists of three subtypes (CNT1,
CNT2, and CNT3), all of which differ in their substrate specificities (32). CNT1 prefers
pyrimidine nucleosides and adenosine, CNT2 prefers purine nucleosides and uridine, and
CNT3 transports both pyrimidine and purine nucleosides. CNTs are primarily found in
barrier cell types such as renal and intestinal epithelia, the blood-brain barrier and bloodtestes barrier, and thus play a role in absorption, distribution and elimination of
nucleosides and their analogues (33).
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1.3.2 Equilibrative Nucleoside Transporters (ENTs)
ENTs are Na+-independent, facilitative diffusion transporters which transport
nucleosides bi-directionally down a concentration gradient. ENTs are widely distributed
among cell types (4,33). The ENT family consists of four members (ENT1, ENT2,
ENT3,and ENT4) which share an ability to transport adenosine but differ in their abilities
to transport other nucleosides and molecules (31). For example, ENT2 has a higher
affinity for inosine than ENT1, and is the only transporter that transports nucleobases. In
addition, many studies reveal that ENT3 has a similar substrate specificity as ENT2, but a
lower affinity (31). The distribution of these transporters is not homogenous among
tissues, and expression is regulated in a cell-type specific manner. ENT orthologues have
been identified in many different eukaryotic species; over the course of evolutionary
time, the protein has been found to be highly conserved, highlighting the physiological
significance of ENTs (34). It should be noted that mice have the same nucleoside
transporter proteins as humans and share similar characteristics (Table 1.1); although
studies to date have suggested that certain ENTs are ubiquitous, expression has yet to be
investigated in all tissues (35).
ENT1 and ENT2 have been the most extensively characterized transporters and
were distinguished based on their sensitivity to inhibition by nitrobenzylthioinosine
(nitrobenzylmercaptopurine riboside; NBMPR). ENT1 is sensitive to inhibition by
NBMPR at ηmolar concentrations and is referred to as the es transporter, or equilibrativesensitive. ENT2 is resistant to inhibition by NBMPR, requiring µmolar concentrations
and is referred to as the ei transporter, or equilibrative-insensitive (Fig. 1.3) (8).

9

Table 1.1: Properties of the mammalian nucleoside transporters (modified from
Young et al., 2008)

10

ENT2

ENT1

Figure 1.3: Mammalian nucleoside transport systems of the equilibrative nucleoside
transporter (ENT) and concentrative nucleoside transporter (CNT) protein families.
(modified from Young et al., 2008)
ENTs are Na+-independent, facilitative diffusion transporters which transport nucleosides
and nucleobases bi-directionally down a concentration gradient. ENT1 and ENT2 are
distinguished based on their sensitivity to inhibition by nitrobenzylthioinosine (NBMPR).
ENT1 is sensitive to inhibition by NBMPR at nanomolar concentrations. ENT2 is
resistant to inhibition by NBMPR. CNTs are Na+-dependent symporters that move
nucleosides and nucleobases against a concentration gradient.

11

ENT1 is ubiquitously distributed in human and rodent tissues, but abundance
varies from tissue to tissue. For example, human ENT1 (hENT1) is most abundant in the
frontal and parietal lobes of the cortex, thalamus and basal ganglia (36). hENT1
expression has also been noted in the brain, heart, liver, placenta, adrenal gland,
erythrocytes, stomach and vascular endothelium (37). With respect to mouse ENT1 (he),
expression has been found in similar tissues such as the heart, brain, and liver, as well as
the colon, spleen, and kidney (35). Although ENT1 is primarily found on the surface of
cells, functional hENT1 has also been associated with the membranes of the endoplasmic
reticulum and nuclear envelope, suggesting that this transporter may play a role in the
passage of nucleosides between these compartments and the cytosol (38). A stark
difference that should be noted is that hENT1 has also been found functionally expressed
in the mitochondria, whereas mENT1 has no association with the mitochondria (39,40).
ENT2 differs from ENT1 in its ability to transport nucleobases such as
hypoxanthine, in addition to nucleosides (31,41). mENT2 mRNA has been identified in a
variety of tissues such as the small intestine, kidney, spleen, heart, and liver, but is
particularly abundant in skeletal muscle (35).
ENT3 and ENT4 are less characterized but appear to have a more specialized role
in the cell (8,42). The ENT3 transcript and protein is abundant in many human and rodent
tissues but is highly expressed in placental tissue (42). Unlike ENT1 and ENT2, ENT3 is
not found at the plasma membrane, but rather is located on intracellular membranes (42).
ENT3 contains an endosomal/lysosomal characteristic motif, which along with its ability
to optimally function at a pH of 5.5, suggests that the location of the transporter is in an
acidic, intracellular compartment such as the lysosome (8,42,43). ENT4, present at the
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cell surface, was originally identified as a monoamine/organic transporter and was named
plasma membrane monoamine transporter (PMAT), since it transports organic cations
such as MPP+, dopamine and serotonin (44-46). It was later discovered that ENT4 was
able to efficiently transport adenosine at an acidic pH of 5.5 (47), and hypothesized to
contribute in the regulation of extracellular adenosine concentrations under acidic
conditions associated with ischemia (8). ENT4 is expressed primarily in the heart, liver
and brain (8).
It is important to note that the reason and degree of functional redundancy
between ENTs is not known; it is unclear why so many cells and tissues express multiple
nucleoside transporters with similar or overlapping substrate selectivity (35).

1.4 ENT1-null mice (ENT1-/-)
The ENT1-/- mouse was created by Dr. Doo-Sup Choi at the Mayo Clinic College
of Medicine. The ENT1-/- mouse was generated on a C57BL/6J x 129X1/SyJ background
using the targeting vector pKSloxPNT-mod to delete coding exons 2 to 4 (Fig. 1.4). This
targeting strategy eliminated 425 of the 1380 base pairs in the protein coding-region (48)
and produced a non-functional protein.
Initial studies demonstrated that at 3 months of age, ENT1-/- mice had <10% lower
body weight, but showed no differences in open-field locomotor activity, and had no
evidence of gross anatomical abnormalities in the brain compared to their wild-type (WT)
littermate controls (48). There were also no significant differences reported in
spontaneous mortality rates up to 6 months of age.
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Figure 1.4: Generation of ENT1-null mice. (modified from Choi et al., 2004)
Figure shows the organization of the gene encoding mouse ENT1, the targeting construct,
and the allele resulting from homologous recombination. Boxes represent the targeted
exons (2–4), which span 425 base pairs. Gray arrowheads represent loxP sequences, the
recognition sites for Cre recombination, and deleted coding exons 2-4.
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These mice were developed to investigate the role of adenosine transport in the
central nervous system pathways regulating alcohol consumption (48,49). In these
studies, ENT1-/- mice consumed significantly higher amounts of ethanol, and had a greater
preference for ethanol than water. Despite the increase in ethanol consumption, these
mice demonstrated a decreased ataxic effect of ethanol. This behavior was associated
with a reduced stimulation of A1 receptors due to a decrease in endogenous adenosine
tone and not due to the loss of A1 receptors or a decrease in A1 receptor affinity (48).
ENT1-/- mice have also been shown to exhibit reduced anxiety-like behaviors, specifically
mediated by A1 receptors (49).
Previous studies in the Hammond lab established that microvascular endothelial
cells (MVECs) isolated from ENT1-/- mice demonstrate compromised nucleoside
transport compared to cells isolated from WT controls. There was no compensation
reported for the loss of ENT1 by other transporters (50). In contrast, MVECs isolated
from ENT1-/- mice show an increase in the A2a receptor and adenosine deaminase (Ada)
mRNA transcript and protein compared to WT cells (50). Ada is a metabolic enzyme that
converts adenosine to a related nucleoside, known as inosine. At 2-3 months of age,
ENT1-/- mice were also found to have a significantly lower blood pressure, possibly due
to the 2.8-fold increase reported in circulating adenosine concentrations. Furthermore,
others have demonstrated that cardiomyocytes from ENT1-/- mice appear to be protected
from ischemic insult and that ENT1-/- mice show decreased myocardial infarction in
response to ischemia and hypoxia (10).
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1.5 Connective Tissues
During previous studies in the Hammond lab using the ENT1-/- mice, it was
observed that these mice develop a mineralized soft connective tissue phenotype.
Connective tissue is the most diverse tissue type with a wide variety of functions; it can
be considered the “glue” that holds the body together. All forms of connective tissue are
made up of: (i) extracellular matrix molecules, (ii) amorphous matrix called ground
substance, and (iii) stationary and migrating cells (51). Depending on the structural
requirements, the proportions of these three components vary from one part of the body
to another. The extracellular matrix (ECM) consists of collagenous, elastic, and reticular
fibers. The amorphous matrix surrounds the cellular and fibrous components and is made
up of glycosaminoglycans (GAGs), proteoglycans (PGs) and glycoproteins. Fibroblasts
are the principle cells of connective tissue that synthesize all of the ECM components
(collagen, elastic and reticular fibers, and the complex carbohydrates of the ground
substance) (52). Specialized connective tissue includes cartilage, blood, bone, ligaments,
and intervertebral discs.
1.5.1 Cartilage
Cartilage is an avascular and aneural tissue composed of two distinct components,
chondrocytes and the ECM (53). Chondrocytes are specialized cells of mesenchymal
origin that produce and, to some degree, maintain the cartilage tissue. More than 95% of
the cartilage volume consists of the ECM, which is the functional element of this tissue
(53,54). Despite the low fraction of chondrocytes in the cartilage, these cells are
important as they produce the matrix that provides mechanical stability to the tissue
(52,54). The composition of the ECM is important to the survival of chondrocytes; the
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large ratio of GAGs to type II collagen fibers in the matrix allow for the diffusion of
nutrients from blood vessels in surrounding tissue to the chondrocytes (52).
Cartilage is a key tissue in the development of the fetal skeleton and growing
bones (52). In healthy cartilage, physiological remodeling of the cartilage is
accomplished through a balance between matrix synthesis and matrix degradation (55).
Based on the characteristics of their matrix, there are three types of cartilage that differ in
appearance and properties: hyaline cartilage, elastic cartilage and fibrocartilage.
1.5.2 Hyaline cartilage, elastic cartilage and fibrocartilage
Hyaline cartilage consists predominantly of type II collagen fibers, GAGs, PGs,
and glycoproteins and is found on the articular surfaces of synovial joints, costal
cartilages of the rib cage, the nasal cavity and the trachea. In early fetal development,
hyaline cartilage forms the template for the skeleton, acting as the precursor of bones that
develop by endochondral ossification (56).
Elastic cartilage is characterized by the presence of elastic fibers within an ECM
with a composition otherwise similar to hyaline cartilage; the elastin fibers and collagen
are arranged in a wavy pattern that makes it flexible. It is found in the outer ear and the
epiglottis of the larynx. In contrast to hyaline cartilage, elastic cartilage does not calcify
with age (52).
Fibrocartilage is rich in type I collagen fibers in addition to the ECM
composition of hyaline cartilage; it is a combination of dense regular connective tissue
and hyaline cartilage (52). It is the only type of cartilage that contains type I collagen in
addition to the normal type II. Fibrocartilage is a tough form of cartilage that consists of
rows of chondrocytes in lacunae between parallel bundles of collagenous fibers, which
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allow the tissue to be strong and flexible. Fibrocartilage lacks a perichondrium, which is a
layer of dense irregular connective tissue that surrounds the cartilage of developing bone,
and can be found around hyaline and elastic cartilage. Fibrocartilage is present in the
annulus fibrosus of intervertebral discs (IVDs), menisci of the knee joint, articular discs
of the sternoclavicular and temporomandibular joints, the pubic symphysis and certain
insertion points of tendons (52). Fibrocartilage is a transitional tissue where soft
connective tissues anchor into bone or cartilage, especially at joints. Fibrocartilage at
these locations serves as a shock absorber, and provides resistance to both compressive
and shearing forces (52). The tissue provides support and rigidity to attached and
surrounding structures, and is the strongest of the three types of cartilage.

1.6 Fibrocartilaginous Tissues of the Axial Skeleton
1.6.1 The Intervertebral Disc
The vertebral column makes up a part of the axial skeleton, and supports the head
and encloses the spinal cord. It consists of alternating vertebral body (VB) bones and soft
connective tissue IVDs. The mouse vertebral column can be divided into five distinct
regions: cervical (7 vertebrae), thoracic (13 vertebrae), lumbar (6 vertebrae), sacral (4
fused vertebrae), and caudal (28 vertebrae) (57,58).
The IVD is a specialized connective tissue that: protects against mechanical
loading delivered by the body mass; acts as the spine’s shock absorbing system; and
provides limited vertebral motion, such as extension and flexion (59,60). The IVD is
composed of three distinct yet interdependent tissues: 1) nucleus pulposus (NP);
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2) annulus fibrosus (AF) (inner annulus fibrosus, IAF; outer annulus fibrosus, OAF); and
3) cartilage endplates (CEP) (Fig. 1.5).
The NP is a highly-hydrated gelatinous tissue in the center of the IVD, formed
from the embryonic notochord (61). The NP is rich in proteoglycans and water and is
held together by a network of type II collagen and elastin fibers. It contains two distinct
cell types, the larger notochordal cells and their smaller mature derivatives known as
chondrocyte-like nucleus pulposus cells (61,62). The major proteoglycan of the NP is
aggrecan, which is a high molecular weight proteoglycan, that consists of 100-150
sulfated GAG chains (such as chondroitin sulfate and keratin sulfate) attached to a
protein core (63). The negatively charged GAG chains of aggrecan draw in water (64),
and allows the NP to distribute hydraulic pressure in all directions, enabling the IVD to
resist compression and maintain its height and turgor (65-67). The amount of water in the
NP varies throughout the day, depending on the activity (60).
The fibrocartilaginous AF makes up the peripheral portion of the disc, which
serves to contain and protect the NP. The cells of the OAF have been described as
fibroblast-like, while the cells in the IAF are more rounded. The IAF is rich in
proteoglycans and type II collagen, where GAGs are intertwined between bundles of
collagen (68,69). The IAF has the appearance of lamellae and is a specialized structure as
it serves as the transition zone between the gelatinous NP and the ligamentous-like outer
part of the annulus fibrosus, the OAF (61,70). The composition and organization of the
OAF is more ligamentous and is formed by concentric lamellae, consisting mainly of
type I collagen. The type 1 collagen fibers of the AF run in oblique sheets, and serve to
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Axial

Figure 1.5: Schematic overview of an intervertebral disc (IVD). (Modified from Kurtz
S, Edidin A. Spine Technology Handbook. 1 edn. Elsevier Academic Press, 2006)
Figure shows the gelatinous nucleus pulposus in the centre, surrounded by the fibrous
annulus fibrosus, and the cartilaginous endplates adjacent to the vertebral body. The
lamellar structure of the annulus fibrosus is also evident. Orientation of the IVD is
denoted as axial, radial and circumferential.
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anchor into the adjacent vertebral endplate (70,71). The direction of these fibers in
successive layers alternate, with one layer crossing the other at angles of 30-60 degrees;
this property provides tensile strength to the annulus fibrosus, allowing it to be stretched
or extended.
The endplates are distinct regions found above and below the IVD between
adjacent vertebrae. The CEP consists of a thin layer of hyaline cartilage between the disc
and vertebral bodies, and similarly, is rich in type II collagen and proteoglycans (72,73).
Through diffusion, the CEP supplies nutrients from blood vessels in the vertebral body to
the inner two-thirds of the AF and the entire NP (74).
1.6.2 Paraspinal Ligaments
Ligaments are a type of dense connective tissue, where fiber bundles run in a
parallel arrangement to provide tensile strength. Paraspinal ligaments are fibrous bands of
dense connective tissue; and serve to provide structural flexibility, strength and stability
to the vertebral column (Fig. 1.6). There are two main ligaments termed the anterior
longitudinal ligament (ALL) and the posterior longitudinal ligament (PLL). The ALL is
a thick, broad fibrous band that lies on the anterior surface of the VBs and IVDs and
prevents hyperextension of the spine. The PLL runs on the posterior surface of the VBs
and IVDs inside the spinal canal and prevents hyperflexion of the spine; the ligament is
narrower and weaker than the ALL (75). The ALL and PPL merge with the AF of the
IVD and are well innervated (76). There are also additional ligaments associated with the
spine that provide further support and strength. The ligamentum flavum is a thick
ligament which connects laminae of adjacent vertebrae and is part of the posterior wall of
the vertebral column. There are also two ligaments that connect neighboring spinous
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Figure 1.6: Schematic overview of paraspinal ligaments associated with the
vertebral column. (Reproduced from: Save Your Aching Back and Neck, A Patient's
Guide by Eidelson, 2002)
Figure shows the organization of the paraspinal ligaments that provide structural
flexibility, strength and stability to the vertebral column. The paraspinal ligaments consist
of the anterior longitudinal ligament, posterior longitudinal ligament, ligamentum flavum,
interspinous ligament, supraspinous ligament, intertransverse ligament, and the facet
capsulary ligament.
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processes, portions of the vertebrae that extend towards the back. The interspinous
ligament runs between the top and bottom of the processes, whereas the supraspinous
ligament is a stronger ligament found along the posterior surface (75). These ligaments
insert into the bone, through fibrocartilaginous intermediate regions.
1.6.3 Sternum
The sternum is an elongated, flattened bone which forms the middle anterior
portion of the thorax, and its margins connect with the cartilages of the first seven pairs
of ribs (75). In humans, the sternum consists of three parts: the manubrium, the body, and
the xiphoid process (77). It is important to note that before puberty, the body of the
sternum consists of four sternebrae which eventually fuse to form one structure; however
this is not the case in mice (77,78). The sternum in mice is made up of six components:
the manubrium (rostral), followed by three separate sternebrae, the xiphisternum, and the
xiphoid cartilage (58). In humans, the sternomanubrial joint (between the sternum and
manubrium) is considered a cartilaginous joint, where the articulating ends are covered
by hyaline cartilage and linked by fibrocartilage and ligaments (79).

1.7 Extracellular Matrix Calcification
Biological mineralization is a cell-regulated event that, under normal
physiological conditions, is restricted to the extracellular matrices of bone, dentin,
cementum, enamel and cartilage. Mineral deposition is an extremely balanced and tightly
controlled process (80). There appears to be two fundamental models for how mineral
deposition in bone is initiated: the cell-mediated model and the matrix-regulated model.
In the cell-mediated model, authors suggest that osteoblasts, which are bone forming
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cells, secrete matrix vesicles (MVs) which control the initial site of mineral deposition
(52). In a mineralization-inducing environment, MVs are proposed to bud off of the outer
cell plasma membrane in a polarized manner towards newly formed osteoid (81). Several
studies suggest that as MVs initially bud off, the vesicles do not contain crystals, but
rather that the first crystalline mineral appears after the MV has been immobilized in the
collagen matrix (81). These vesicles contain enzymes, and accumulate calcium (Ca2+)
and inorganic phosphate (Pi or PO43-). These components allow for the crystallization of
calcium

phosphate,

leading

to

the

formation

of

initial

hydroxyapatite

(HA, Ca10(PO4)6(OH)2) crystals within the lumen of MVs (82). Once the mineral has
reached a certain size, the MV ruptures, and initial crystals of HA grow rapidly to join
crystals produced around other matrix vesicles, contributing to extracellular matrix
calcification (81,83). It should be noted that the mechanism by which MVs accumulate
Ca2+ and Pi, and the mechanism by which crystals penetrate through the membrane are
not yet fully understood.
On the other hand, it has been proposed that the extracellular matrix mineralizes
directly, without the involvement of matrix vesicles (84,85). This matrix-regulated model
states that all components necessary for the initiation and deposition of calcification are
an inherent property of the extracellular matrix once they have been secreted. It has been
suggested that nucleation occurs within gaps of the collagen bundles and crystals
subsequently grow, mediated by certain non-collagenous proteins, which associate with
the extracellular matrix (84,85).
In bone, there are several events that occur to enable mineralization (52). First,
alkaline phosphatase (ALPL) increases the Pi concentration, and hydrolyzes the
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mineralization inhibitor, PPi. It is known that PPi antagonizes the formation of HA
crystals, hence the importance of having a tight balance between the levels of
extracellular Pi and PPi for normal mineral deposition (86). Bone sialoprotein (BSP),
which is a major protein in the mineralized matrix of bone has been proposed to nucleate
crystals, and initiate the deposition of calcium phosphate (87,88). BSP and several other
bone proteins play a critical role in the growth of crystals, and extracellular matrix
calcification.
Many genes involved in regulating mineral deposition have been identified (Fig.
1.2). ATP is released by as yet unresolved pathway into the extracellular fluid, and
metabolized by cell-surface enzymes, such as ectonucleotide pyrophosphatase/
phosphodiesterase 1 (ENPP1), which releases PPi (13). Extracellular PPi levels can also
be regulated by progressive ankylosis (ANK), a transmembrane protein postulated to
mediate PPi efflux [84]. PPi is metabolized by the cell-surface enzyme ALPL, to Pi,
which promotes mineralization. The Nt5e gene encodes ecto-5’-nucleotidase (CD73), an
enzyme that converts AMP to adenosine and Pi. Matrix gla protein (MGP) (89) and
osteopontin (SPP1) (90) are matrix proteins that inhibit mineralization.

1.8 Disorders of Tissue Mineralization
Abnormal calcification of the ECM of soft connective tissues is associated with a
number of pathologies including vascular disease, chronic kidney disease, and skeletal
disorders (91-94). Soft tissues do not mineralize under normal conditions but, under
certain pathological conditions, tissues such as articular cartilage and cardiovascular
tissues are prone to mineralization (95,96). Mutations in many of the genes (mentioned in

25

section 1.7, and Fig. 1.2) affect the rate of generation, transport and degradation of PPi,
leading to an unbalanced level, which ultimately leads to ectopic deposition of mineral
(12-15,86). For example, a study showed that mutations in the gene encoding ENPP1
have been associated with a hypermineralization disorder known as idiopathic infantile
arterial calcification (13). In mice, mutations of Ank lead to arthritis, ectopic crystal
formation and joint fusion throughout the body (97); in humans, dominant mutations
were associated with craniometaphyseal dysplasia (98). A study by Yadav et al. reports
that a disruption in Alpl prevents skeletal mineralization (15). MGP deficiency in mice
resulted in premature calcification, and aberrant mineralization in normal cartilage
including the growth plate, which eventually lead to short stature, osteopenia and
fractures, and severe arterial calcification, which lead to premature death (99).
1.8.1 Ossification of the Posterior Longitudinal Ligament and Diffuse Idiopathic
Skeletal Hyperostosis
Ossification of paraspinal ligaments is identified in the middle-aged and elderly,
and can be diagnosed as one of two non-inflammatory conditions: (1) ossification of the
posterior longitudinal ligament (OPLL), or diffuse idiopathic skeletal hyperostosis
(DISH, formally known as Forestier disease (100)).
OPLL is the abnormal calcification of the posterior longitudinal ligament, and has
the highest incidence in Japan (101). OPLL is commonly detected in the cervical region
of the spine, where lesions can compress the spinal cord resulting in neurological
complications. This condition is twice as common in woman and symptoms often
present between the ages of 50 to 60 (102). Since OPLL is commonly found in Asian
populations, genetic factors are believed to play a role in its development. Many genes
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have been associated with OPLL, including polymorphisms in collagen 11A2
(COL11A2) (103), collagen 6A1 (COL6A1) (104) and mutations in ectonucleotide
pyrophosphatase/phosphodiesterase 1 (ENPP1) (105).
The overall prevalence of DISH is estimated to be around 6-12% of North
Americans (106). As reported by The Arthritis Society, DISH is the second most common
form of arthritis, after osteoarthritis. DISH involves the pathological calcification of the
anterolateral spinal ligaments, at ligamentous attachments known as entheses, and paraarticular soft tissues (107-109). DISH is a progressive condition in which calcifications
accumulate over many years forming flowing calcified material along sides of the spine
vertebrae (Fig. 1.7). DISH is often underdiagnosed and widely misdiagnosed (110). It is
predominantly diagnosed though radiographs of the thoracic spine or chest, which reveal
distinct calcified outgrowths along the vertebrae (111). There are three radiographic
criteria for DISH: 1) flowing calcifications along anterolateral aspect of at least four
continuous vertebral bodies; 2) preservation of disc height in involved areas (in contrast
to degenerative disc disease); and 3) absence of bony ankylosis of facet joints and
absence of sacroiliac erosion, sclerosis or fusion (in contrast to ankylosing spondylitis)
(112). DISH often presents as back pain and stiffness, and is associated with increased
vertebral fractures in the elderly (113) and in severe cases, dysphagia (114) and
compression of the spinal cord and nerve roots (114-116). To date, no single gene defect
has been associated with DISH; however single nucleotide polymorphisms in the
COL6A1 and FGF2 genes have been shown to confer genetic susceptibility to DISH
(117,118). The etiology of DISH is unknown; however numerous studies have associated
obesity, hypertension, diabetes mellitus, hyperinsulinemia, dyslipidemia, elevated growth
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Figure 1.7: Diffuse idiopathic skeletal hyperostosis (DISH) in 55-year-old man.
(Reproduced from: Journal of Clinical Neuroscience 17: 336-1338, 2010)
Computed tomography scan in the sagittal orientation of the cervical region shows
ventral calcifications at the level of C4 to C6 (white arrow). Patient presented with a
history of progressive dysphagia, associated with neck stiffness.
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hormone levels, elevated insulin-like growth factor-1, and hyperuricemia with DISH
(119-121). Pathological findings of DISH have been reported in the anterior longitudinal
ligament, paraspinal connective tissue, and annulus fibrosus of the intervertebral disc
(112); lesions are thought to originate in fibrocartilaginous structures including entheses
(122).

1.9 Rationale, Objectives and Hypotheses
Preliminary observations suggest that mice lacking the gene encoding ENT1
developed lesions of ectopic mineralization which resemble DISH in humans. With
advanced age, ENT1-/- mice displayed a stiff back, hind limb dysfunction and eventual
hind limb paralysis at 12 months of age. Preliminary micro-computed tomography (µCT)
scans and histological analyses revealed hypermineralized lesions began in the cervicalthoracic region of the spine and extended towards the lumbar region with advanced age.
Since the etiology and mechanism of DISH is unknown, the ENT1-/- mouse may
provide a model to investigate mechanisms underlying ectopic mineralization and
evaluate therapeutics for preventing pathological calcification in DISH and related
disorders. The ultimate goal of this study was to investigate how the loss of the gene
encoding ENT1 leads to the aberrant skeletal phenotype demonstrated in the ENT1-/mice. Specifically, it was hypothesized that: loss of ENT1 leads to progressive
accumulation of ectopic mineral in paraspinal tissues due to altered expression of
genes that regulate biomineralization.
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We sought to explore this hypothesis with the following specific objectives:
1) Characterize pathological changes in paraspinal tissues in ENT1-/- mice over time
pertaining specifically to hypermineralization.
2) Determine changes in the expression of genes associated with adenosine transport
and metabolism, as well as, extracellular matrix mineralization in the ENT1-/mice compared to wild-type controls.

30

1.10 References
1.

Callahan MP, Smith KE, Cleaves HJ, 2nd, Ruzicka J, Stern JC, Glavin DP, House
CH, Dworkin JP 2011 Carbonaceous meteorites contain a wide range of
extraterrestrial nucleobases. Proc Natl Acad Sci U S A 108(34):13995-8.

2.

Andre A, Guschlbauer W 1974 Nucleoside conformations. 15. Flexibility of
natural pyrimidine nucleosides around the glycosidic bond. Nucleic Acids Res
1(6):803-7.

3.

Goodman G, Gershwin ME, Bercovich D 2012 Fullerene and the origin of life. Isr
Med Assoc J 14(10):602-6.

4.

Baldwin SA, Mackey JR, Cass CE, Young JD 1999 Nucleoside transporters:
molecular biology and implications for therapeutic development. Mol Med Today
5(5):216-24.

5.

Porkka-Heiskanen T, Kalinchuk AV 2011 Adenosine, energy metabolism and
sleep homeostasis. Sleep Med Rev 15(2):123-35.

6.

Neary JT, Rathbone MP, Cattabeni F, Abbracchio MP, Burnstock G 1996 Trophic
actions of extracellular nucleotides and nucleosides on glial and neuronal cells.
Trends in neurosciences 19(1):13-8.

7.

Galmarini CM, Mackey JR, Dumontet C 2002 Nucleoside analogues and
nucleobases in cancer treatment. Lancet Oncol 3(7):415-24.

8.

Young JD, Yao SY, Sun L, Cass CE, Baldwin SA 2008 Human equilibrative
nucleoside transporter (ENT) family of nucleoside and nucleobase transporter
proteins. Xenobiotica 38(7-8):995-1021.

9.

Clarke ML, Mackey JR, Baldwin SA, Young JD, Cass CE 2002 The role of
membrane transporters in cellular resistance to anticancer nucleoside drugs.
Cancer Treat Res 112:27-47.

10.

Rose JB, Naydenova Z, Bang A, Eguchi M, Sweeney G, Choi DS, Hammond JR,
Coe IR 2010 Equilibrative nucleoside transporter 1 plays an essential role in
cardioprotection. Am J Physiol Heart Circ Physiol 298(3):H771-7.

11.

Mubagwa K, Flameng W 2001 Adenosine, adenosine receptors and myocardial
protection: an updated overview. Cardiovasc Res 52(1):25-39.

12.

Evans BA 2012 Does adenosine play a role in bone formation, resorption and
repair? Purinergic Signal 8(2):177-80.

31

13.

Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Hohne W, Schauer G,
Lehmann M, Roscioli T, Schnabel D, Epplen JT, Knisely A, Superti-Furga A,
McGill J, Filippone M, Sinaiko AR, Vallance H, Hinrichs B, Smith W, Ferre M,
Terkeltaub R, Nurnberg P 2003 Mutations in ENPP1 are associated with
'idiopathic' infantile arterial calcification. Nat Genet 34(4):379-81.

14.

St Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F, CarlsonDonohoe H, Lederman RJ, Chen MY, Yang D, Siegenthaler MP, Arduino C,
Mancini C, Freudenthal B, Stanescu HC, Zdebik AA, Chaganti RK, Nussbaum
RL, Kleta R, Gahl WA, Boehm M 2011 NT5E mutations and arterial
calcifications. N Engl J Med 364(5):432-42.

15.

Yadav MC, Simao AM, Narisawa S, Huesa C, McKee MD, Farquharson C,
Millan JL 2011 Loss of skeletal mineralization by the simultaneous ablation of
PHOSPHO1 and alkaline phosphatase function: a unified model of the
mechanisms of initiation of skeletal calcification. J Bone Miner Res 26(2):286-97.

16.

Fredholm BB, AP IJ, Jacobson KA, Linden J, Muller CE 2011 International
Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and
classification of adenosine receptors--an update. Pharmacol Rev 63(1):1-34.

17.

Olah ME, Stiles GL 2000 The role of receptor structure in determining adenosine
receptor activity. Pharmacol Ther 85(2):55-75.

18.

Nishat S, Shabir H, Azmi AS, Ansari HR 2012 A(3) adenosine receptor: a
plausible therapeutic target for cardio-protection in diabetes. Recent Pat
Cardiovasc Drug Discov 7(1):59-70.

19.

Prosdocimo DA, Wyler SC, Romani AM, O'Neill WC, Dubyak GR 2010
Regulation of vascular smooth muscle cell calcification by extracellular
pyrophosphate homeostasis: synergistic modulation by cyclic AMP and
hyperphosphatemia. Am J Physiol Cell Physiol 298(3):C702-13.

20.

Neve A, Corrado A, Cantatore FP 2011 Osteoblast physiology in normal and
pathological conditions. Cell Tissue Res 343(2):289-302.

21.

Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ 1999
Modulation of osteoclast differentiation and function by the new members of the
tumor necrosis factor receptor and ligand families. Endocr Rev 20(3):345-57.

22.

Kara FM, Chitu V, Sloane J, Axelrod M, Fredholm BB, Stanley ER, Cronstein
BN 2010 Adenosine A1 receptors (A1Rs) play a critical role in osteoclast
formation and function. FASEB J 24(7):2325-33.

23.

He W, Cronstein B 2011 The roles of adenosine and adenosine receptors in bone
remodeling. Front Biosci (Elite Ed) 3:888-95.

32

24.

He W, Cronstein BN 2012 Adenosine A1 receptor regulates osteoclast formation
by altering TRAF6/TAK1 signaling. Purinergic Signal 8(2):327-37.

25.

Mediero A, Kara FM, Wilder T, Cronstein BN 2012 Adenosine A(2A) receptor
ligation inhibits osteoclast formation. Am J Pathol 180(2):775-86.

26.

Gharibi B, Abraham AA, Ham J, Evans BA 2011 Adenosine receptor subtype
expression and activation influence the differentiation of mesenchymal stem cells
to osteoblasts and adipocytes. J Bone Miner Res 26(9):2112-24.

27.

Katebi M, Soleimani M, Cronstein BN 2009 Adenosine A2A receptors play an
active role in mouse bone marrow-derived mesenchymal stem cell development. J
Leukoc Biol 85(3):438-44.

28.

Carroll SH, Wigner NA, Kulkarni N, Johnston-Cox H, Gerstenfeld LC, Ravid K
2012 A2B adenosine receptor promotes mesenchymal stem cell differentiation to
osteoblasts and bone formation in vivo. J Biol Chem 287(19):15718-27.

29.

Evans BA, Elford C, Pexa A, Francis K, Hughes AC, Deussen A, Ham J 2006
Human osteoblast precursors produce extracellular adenosine, which modulates
their secretion of IL-6 and osteoprotegerin. J Bone Miner Res 21(2):228-36.

30.

Costa MA, Barbosa A, Neto E, Sa-e-Sousa A, Freitas R, Neves JM, MagalhaesCardoso T, Ferreirinha F, Correia-de-Sa P 2011 On the role of subtype selective
adenosine receptor agonists during proliferation and osteogenic differentiation of
human primary bone marrow stromal cells. J Cell Physiol 226(5):1353-66.

31.

Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD 2004 The
equilibrative nucleoside transporter family, SLC29. Pflugers Arch 447(5):735-43.

32.

Gray JH, Owen RP, Giacomini KM 2004 The concentrative nucleoside
transporter family, SLC28. Pflugers Arch 447(5):728-34.

33.

King AE, Ackley MA, Cass CE, Young JD, Baldwin SA 2006 Nucleoside
transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci
27(8):416-25.

34.

Acimovic Y, Coe IR 2002 Molecular evolution of the equilibrative nucleoside
transporter family: identification of novel family members in prokaryotes and
eukaryotes. Mol Biol Evol 19(12):2199-210.

35.

Graham K, Yao S, Johnson L, Mowles D, Ng A, Wilkinson J, Young JD, Cass CE
2011 Nucleoside transporter gene expression in wild-type and mENT1 knockout
mice. Biochem Cell Biol 89(2):236-45.

33

36.

Jennings LL, Hao C, Cabrita MA, Vickers MF, Baldwin SA, Young JD, Cass CE
2001 Distinct regional distribution of human equilibrative nucleoside transporter
proteins 1 and 2 (hENT1 and hENT2) in the central nervous system.
Neuropharmacology 40(5):722-31.

37.

Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR 2001 Differential
expression of human nucleoside transporters in normal and tumor tissue. Biochem
Biophys Res Commun 280(3):951-9.

38.

Mani RS, Hammond JR, Marjan JM, Graham KA, Young JD, Baldwin SA, Cass
CE 1998 Demonstration of equilibrative nucleoside transporters (hENT1 and
hENT2) in nuclear envelopes of cultured human choriocarcinoma (BeWo) cells
by functional reconstitution in proteoliposomes. J Biol Chem 273(46):30818-25.

39.

Lai Y, Tse CM, Unadkat JD 2004 Mitochondrial expression of the human
equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial
toxicity of antiviral drugs. J Biol Chem 279(6):4490-7.

40.

Lee EW, Lai Y, Zhang H, Unadkat JD 2006 Identification of the mitochondrial
targeting signal of the human equilibrative nucleoside transporter 1 (hENT1):
implications for interspecies differences in mitochondrial toxicity of fialuridine. J
Biol Chem 281(24):16700-6.

41.

Nagai K, Nagasawa K, Kyotani Y, Hifumi N, Fujimoto S 2007 Mouse
equilibrative nucleoside transporter 2 (mENT2) transports nucleosides and purine
nucleobases differing from human and rat ENT2. Biol Pharm Bull 30(5):979-81.

42.

Baldwin SA, Yao SY, Hyde RJ, Ng AM, Foppolo S, Barnes K, Ritzel MW, Cass
CE, Young JD 2005 Functional characterization of novel human and mouse
equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular
membranes. J Biol Chem 280(16):15880-7.

43.

Sandoval IV, Martinez-Arca S, Valdueza J, Palacios S, Holman GD 2000 Distinct
reading of different structural determinants modulates the dileucine-mediated
transport steps of the lysosomal membrane protein LIMPII and the insulinsensitive glucose transporter GLUT4. J Biol Chem 275(51):39874-85.

44.

Engel K, Wang J 2005 Interaction of organic cations with a newly identified
plasma membrane monoamine transporter. Mol Pharmacol 68(5):1397-407.

45.

Engel K, Zhou M, Wang J 2004 Identification and characterization of a novel
monoamine transporter in the human brain. J Biol Chem 279(48):50042-9.

46.

Zhou M, Engel K, Wang J 2007 Evidence for significant contribution of a newly
identified monoamine transporter (PMAT) to serotonin uptake in the human
brain. Biochem Pharmacol 73(1):147-54.

34

47.

Barnes K, Dobrzynski H, Foppolo S, Beal PR, Ismat F, Scullion ER, Sun L,
Tellez J, Ritzel MW, Claycomb WC, Cass CE, Young JD, Billeter-Clark R,
Boyett MR, Baldwin SA 2006 Distribution and functional characterization of
equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter
activated at acidic pH. Circ Res 99(5):510-9.

48.

Choi DS, Cascini MG, Mailliard W, Young H, Paredes P, McMahon T, Diamond
I, Bonci A, Messing RO 2004 The type 1 equilibrative nucleoside transporter
regulates ethanol intoxication and preference. Nat Neurosci 7(8):855-61.

49.

Chen J, Rinaldo L, Lim SJ, Young H, Messing RO, Choi DS 2007 The type 1
equilibrative nucleoside transporter regulates anxiety-like behavior in mice.
Genes Brain Behav 6(8):776-83.

50.

Bone DB, Choi DS, Coe IR, Hammond JR 2010 Nucleoside/nucleobase transport
and metabolism by microvascular endothelial cells isolated from ENT1-/- mice.
Am J Physiol Heart Circ Physiol 299(3):H847-56.

51.

Cauz J, Anderson R, Barlow G, Bowe W, Healy G, Hoiberg D, Mansoor L, Ross
M 2013 Connective Tissue Encyclopedia Britannica

52.

Ross MP, W 2006 Histology A Text and Atlas With correlated cell and molecular
biology, Fifth ed. Lippincott Williams & Wilkins, Philadelphia, pp 906.

53.

Aigner T, Sachse A, Gebhard PM, Roach HI 2006 Osteoarthritis: pathobiologytargets and ways for therapeutic intervention. Adv Drug Deliv Rev 58(2):128-49.

54.

Responte DJ, Lee JK, Hu JC, Athanasiou KA 2012 Biomechanics-driven
chondrogenesis: from embryo to adult. FASEB J 26(9):3614-24.

55.

Eyre DR 2004 Collagens and cartilage matrix homeostasis. Clin Orthop Relat Res
(427 Suppl):S118-22.

56.

Las Heras F, Gahunia HK, Pritzker KP 2012 Articular cartilage development: a
molecular perspective. Orthop Clin North Am 43(2):155-71, v.

57.

Sofaer JA 1985 Developmental stability in the mouse vertebral column. J Anat
140 ( Pt 1):131-41.

58.

Bab IA, Hajbi-Yonissi, C., Gabet, Y., Müller, R. 2007 Micro-Tomographic Atlas
of the Mouse Skeleton, 2007 ed. Springer, pp 213.

59.

Chan WC, Sze KL, Samartzis D, Leung VY, Chan D 2011 Structure and biology
of the intervertebral disk in health and disease. Orthop Clin North Am 42(4):44764, vii.

35

60.

Bridwell K 2010 Intervertebral Discs, vol. 2013. Vertical Health.

61.

Maldonado BA, Oegema TR, Jr. 1992 Initial characterization of the metabolism
of intervertebral disc cells encapsulated in microspheres. J Orthop Res 10(5):67790.

62.

McCann MR, Tamplin OJ, Rossant J, Seguin CA 2012 Tracing notochord-derived
cells using a Noto-cre mouse: implications for intervertebral disc development.
Dis Model Mech 5(1):73-82.

63.

Nap RJ, Szleifer I 2008 Structure and interactions of aggrecans: statistical
thermodynamic approach. Biophys J 95(10):4570-83.

64.

Johnstone B, Bayliss MT 1995 The large proteoglycans of the human
intervertebral disc. Changes in their biosynthesis and structure with age,
topography, and pathology. Spine (Phila Pa 1976) 20(6):674-84.

65.

Adams MA, Roughley PJ 2006 What is intervertebral disc degeneration, and what
causes it? Spine (Phila Pa 1976) 31(18):2151-61.

66.

Setton LA, Chen J 2006 Mechanobiology of the intervertebral disc and relevance
to disc degeneration. J Bone Joint Surg Am 88 Suppl 2:52-7.

67.

Watanabe H, Yamada Y, Kimata K 1998 Roles of aggrecan, a large chondroitin
sulfate proteoglycan, in cartilage structure and function. J Biochem 124(4):68793.

68.

Oegema TR, Jr. 1993 Biochemistry of the intervertebral disc. Clin Sports Med
12(3):419-39.

69.

Melrose J, Ghosh P, Taylor TK 2001 A comparative analysis of the differential
spatial and temporal distributions of the large (aggrecan, versican) and small
(decorin, biglycan, fibromodulin) proteoglycans of the intervertebral disc. J Anat
198(Pt 1):3-15.

70.

Baer AE, Wang JY, Kraus VB, Setton LA 2001 Collagen gene expression and
mechanical properties of intervertebral disc cell-alginate cultures. J Orthop Res
19(1):2-10.

71.

Wang JY, Baer AE, Kraus VB, Setton LA 2001 Intervertebral disc cells exhibit
differences in gene expression in alginate and monolayer culture. Spine (Phila Pa
1976) 26(16):1747-51; discussion 1752.

72.

Moore RJ 2006 The vertebral endplate: disc degeneration, disc regeneration. Eur
Spine J 15 Suppl 3:S333-7.

36

73.

Roberts S, Menage J, Urban JP 1989 Biochemical and structural properties of the
cartilage end-plate and its relation to the intervertebral disc. Spine (Phila Pa 1976)
14(2):166-74.

74.

Urban JP, Smith S, Fairbank JC 2004 Nutrition of the intervertebral disc. Spine
(Phila Pa 1976) 29(23):2700-9.

75.

Gray H 1918 Anatomy of the Human Body, 20th Ed ed. Lea & Febiger,
Philadelphia, pp 1396.

76.

Timothy J, Foley E, Comer C, Barron D, Sloan J, Shilliday H 2008 Soft tissue
injuries: 3. Paraspinal. Emerg Med J 25(8):514-21.

77.

O'Neal ML, Dwornik JJ, Ganey TM, Ogden JA 1998 Postnatal development of
the human sternum. J Pediatr Orthop 18(3):398-405.

78.

Chen JM 1952 Studies on the morphogenesis of the mouse sternum. I. Normal
embryonic development. J Anat 86(4):373-86.

79.

Parker VS, Malhotra CM, Ho G, Jr., Kaplan SR 1984 Radiographic appearance of
the sternomanubrial joint in arthritis and related conditions. Radiology
153(2):343-7.

80.

Armas JB, Couto AR, Bettencourt BF 2009 Spondyloarthritis, diffuse idiopathic
skeletal hyperostosis (DISH) and chondrocalcinosis. Adv Exp Med Biol 649:3756.

81.

Anderson HC 1995 Molecular biology of matrix vesicles. Clin Orthop Relat Res
(314):266-80.

82.

Ciancaglini P, Simao AM, Camolezi FL, Millan JL, Pizauro JM 2006
Contribution of matrix vesicles and alkaline phosphatase to ectopic bone
formation. Braz J Med Biol Res 39(5):603-10.

83.

Poole AR, Matsui Y, Hinek A, Lee ER 1989 Cartilage macromolecules and the
calcification of cartilage matrix. Anat Rec 224(2):167-79.

84.

Glimcher MJ 1989 Mechanism of calcification: role of collagen fibrils and
collagen-phosphoprotein complexes in vitro and in vivo. Anat Rec 224(2):139-53.

85.

Midura RJ, Wang A, Lovitch D, Law D, Powell K, Gorski JP 2004 Bone acidic
glycoprotein-75 delineates the extracellular sites of future bone sialoprotein
accumulation and apatite nucleation in osteoblastic cultures. J Biol Chem
279(24):25464-73.

37

86.

Terkeltaub RA 2001 Inorganic pyrophosphate generation and disposition in
pathophysiology. Am J Physiol Cell Physiol 281(1):C1-C11.

87.

Bianco P, Fisher LW, Young MF, Termine JD, Robey PG 1991 Expression of
bone sialoprotein (BSP) in developing human tissues. Calcif Tissue Int 49(6):4216.

88.

Chen JK, Shapiro HS, Wrana JL, Reimers S, Heersche JN, Sodek J 1991
Localization of bone sialoprotein (BSP) expression to sites of mineralized tissue
formation in fetal rat tissues by in situ hybridization. Matrix 11(2):133-43.

89.

Sage AP, Tintut Y, Demer LL 2010 Regulatory mechanisms in vascular
calcification. Nat Rev Cardiol 7(9):528-36.

90.

Cho HJ, Kim HS 2009 Osteopontin: a multifunctional protein at the crossroads of
inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep
11(3):206-13.

91.

Demer LL, Tintut Y 2008 Vascular calcification: pathobiology of a multifaceted
disease. Circulation 117(22):2938-48.

92.

Toussaint ND 2011 Extracellular matrix calcification in chronic kidney disease.
Curr Opin Nephrol Hypertens 20(4):360-8.

93.

Persy V, D'Haese P 2009 Vascular calcification and bone disease: the
calcification paradox. Trends Mol Med 15(9):405-16.

94.

Hyder JA, Allison MA, Criqui MH, Wright CM 2007 Association between
systemic calcified atherosclerosis and bone density. Calcif Tissue Int 80(5):301-6.

95.

Giachelli CM 1999 Ectopic calcification: gathering hard facts about soft tissue
mineralization. Am J Pathol 154(3):671-5.

96.

Giachelli CM 2005 Inducers and inhibitors of biomineralization: lessons from
pathological calcification. Orthod Craniofac Res 8(4):229-31.

97.

Ho AM, Johnson MD, Kingsley DM 2000 Role of the mouse ank gene in control
of tissue calcification and arthritis. Science 289(5477):265-70.

98.

Nurnberg P, Thiele H, Chandler D, Hohne W, Cunningham ML, Ritter H, Leschik
G, Uhlmann K, Mischung C, Harrop K, Goldblatt J, Borochowitz ZU, Kotzot D,
Westermann F, Mundlos S, Braun HS, Laing N, Tinschert S 2001 Heterozygous
mutations in ANKH, the human ortholog of the mouse progressive ankylosis
gene, result in craniometaphyseal dysplasia. Nat Genet 28(1):37-41.

38

99.

Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G 1997
Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA
protein. Nature 386(6620):78-81.

100.

Forestier J, Rotes-Querol J 1950 Senile ankylosing hyperostosis of the spine. Ann
Rheum Dis 9(4):321-30.

101.

Tsuyama N 1984 Ossification of the posterior longitudinal ligament of the spine.
Clin Orthop Relat Res (184):71-84.

102.

Saetia K, Cho D, Lee S, Kim DH, Kim SD 2011 Ossification of the posterior
longitudinal ligament: a review. Neurosurg Focus 30(3):E1.

103.

Koga H, Sakou T, Taketomi E, Hayashi K, Numasawa T, Harata S, Yone K,
Matsunaga S, Otterud B, Inoue I, Leppert M 1998 Genetic mapping of
ossification of the posterior longitudinal ligament of the spine. Am J Hum Genet
62(6):1460-7.

104.

Kong Q, Ma X, Li F, Guo Z, Qi Q, Li W, Yuan H, Wang Z, Chen Z 2007
COL6A1 polymorphisms associated with ossification of the ligamentum flavum
and ossification of the posterior longitudinal ligament. Spine (Phila Pa 1976)
32(25):2834-8.

105.

Koshizuka Y, Kawaguchi H, Ogata N, Ikeda T, Mabuchi A, Seichi A, Nakamura
Y, Nakamura K, Ikegawa S 2002 Nucleotide pyrophosphatase gene
polymorphism associated with ossification of the posterior longitudinal ligament
of the spine. J Bone Miner Res 17(1):138-44.

106.

Weinfeld RM, Olson PN, Maki DD, Griffiths HJ 1997 The prevalence of diffuse
idiopathic skeletal hyperostosis (DISH) in two large American Midwest
metropolitan hospital populations. Skeletal Radiol 26(4):222-5.

107.

Mader R, Buskila D, Verlaan JJ, Atzeni F, Olivieri I, Pappone N, Di Girolamo C,
Sarzi-Puttini P 2012 Developing new classification criteria for diffuse idiopathic
skeletal hyperostosis: back to square one. Rheumatology (Oxford).

108.

Krishnarasa B, Vivekanandarajah A, Ripoll L, Chang E, Wetz R 2011 Diffuse
Idiopathic Skeletal Hyperostosis (DISH)-A Rare Etiology of Dysphagia. Clin
Med Insights Arthritis Musculoskelet Disord 4:71-5.

109.

Resnick D, Shaul SR, Robins JM 1975 Diffuse idiopathic skeletal hyperostosis
(DISH): Forestier's disease with extraspinal manifestations. Radiology
115(3):513-24.

110.

Verdone F 2010 Diffuse idiopathic skeletal hyperostosis in the third millennium:
is there (yet) cause for concern? J Rheumatol 37(6):1356-7; author reply 1358.

39

111.

Belanger TA, Rowe DE 2001 Diffuse idiopathic skeletal hyperostosis:
musculoskeletal manifestations. J Am Acad Orthop Surg 9(4):258-67.

112.

Resnick D, Niwayama G 1976 Radiographic and pathologic features of spinal
involvement in diffuse idiopathic skeletal hyperostosis (DISH). Radiology
119(3):559-68.

113.

Diederichs G, Engelken F, Marshall LM, Peters K, Black DM, Issever AS,
Barrett-Connor E, Orwoll E, Hamm B, Link TM 2011 Diffuse idiopathic skeletal
hyperostosis (DISH): relation to vertebral fractures and bone density. Osteoporos
Int 22(6):1789-97.

114.

Seidler TO, Perez Alvarez JC, Wonneberger K, Hacki T 2009 Dysphagia caused
by ventral osteophytes of the cervical spine: clinical and radiographic findings.
Eur Arch Otorhinolaryngol 266(2):285-91.

115.

Wilson FM, Jaspan T 1990 Thoracic spinal cord compression caused by diffuse
idiopathic skeletal hyperostosis (DISH). Clin Radiol 42(2):133-5.

116.

Johnsson KE, Petersson H, Wollheim FA, Saveland H 1983 Diffuse idiopathic
skeletal hyperostosis (DISH) causing spinal stenosis and sudden paraplegia. J
Rheumatol 10(5):784-9.

117.

Jun JK, Kim SM 2012 Association study of fibroblast growth factor 2 and
fibroblast growth factor receptors gene polymorphism in korean ossification of
the posterior longitudinal ligament patients. J Korean Neurosurg Soc 52(1):7-13.

118.

Tsukahara S, Miyazawa N, Akagawa H, Forejtova S, Pavelka K, Tanaka T, Toh
S, Tajima A, Akiyama I, Inoue I 2005 COL6A1, the candidate gene for
ossification of the posterior longitudinal ligament, is associated with diffuse
idiopathic skeletal hyperostosis in Japanese. Spine (Phila Pa 1976) 30(20):2321-4.

119.

Kiss C, Szilagyi M, Paksy A, Poor G 2002 Risk factors for diffuse idiopathic
skeletal hyperostosis: a case-control study. Rheumatology (Oxford) 41(1):27-30.

120.

Mader R, Lavi I 2009 Diabetes mellitus and hypertension as risk factors for early
diffuse idiopathic skeletal hyperostosis (DISH). Osteoarthritis Cartilage
17(6):825-8.

121.

Mader R, Novofestovski I, Adawi M, Lavi I 2009 Metabolic syndrome and
cardiovascular risk in patients with diffuse idiopathic skeletal hyperostosis. Semin
Arthritis Rheum 38(5):361-5.

122.

Mader R 2008 Diffuse idiopathic skeletal hyperostosis: time for a change. J
Rheumatol 35(3):377-9.

40

Chapter 2

Loss of Equilibrative Nucleoside Transporter 1 (ENT1) in Mice Leads
to Progressive Ectopic Mineralization of Spinal Tissues Resembling
Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Humans

This chapter has been modified from: Warraich S, Bone DBJ, Quinonez D, Ii H, Choi
DS, Holdsworth DW, Drangova M, Dixon SJ, Séguin CA, and Hammond JR. Loss of
Equilibrative Nucleoside Transporter 1 (ENT1) in Mice Leads to Progressive Ectopic
Mineralization of Spinal Tissues Resembling Diffuse Idiopathic Skeletal Hyperostosis
(DISH) in Humans. J Bone Miner Res. 2013 May;28(5):1135-49. doi:10.1002/jbmr.1826.
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2.1 Chapter Summary
Diffuse idiopathic skeletal hyperostosis (DISH) is a non-inflammatory
spondyloarthropathy, characterized by ectopic calcification of spinal tissues. Symptoms
include spine pain and stiffness, and in severe cases dysphagia and spinal cord
compression. The etiology of DISH is unknown and there are no specific treatments.
Recent studies have suggested a role for purine metabolism in the regulation of
biomineralization. Equilibrative nucleoside transporter 1 (ENT1) transfers hydrophilic
nucleosides, such as adenosine, across the plasma membrane. In mice lacking ENT1, we
observed the development of calcified lesions resembling DISH. By 12 months of age,
ENT1-/- mice exhibited signs of spine stiffness, hind limb dysfunction, and paralysis.
Micro-CT revealed ectopic mineralization of paraspinal tissues in the cervical-thoracic
region at 2 months of age, which extended to the lumbar and caudal regions with
advancing age. Energy-dispersive X-ray microanalysis of lesions revealed a high content
of calcium and phosphorus with a ratio similar to that of cortical bone. At 12 months of
age, histological examination of ENT1-/- mice revealed large, irregular accumulations of
eosinophilic material in paraspinal ligaments and entheses, intervertebral discs and
sternocostal articulations. There was no evidence of mineralization in appendicular joints
or blood vessels, indicating specificity for the axial skeleton. Plasma adenosine levels
were significantly greater in ENT1-/- mice than in wild-type, consistent with loss of ENT1
– a primary adenosine uptake pathway. There was a significant reduction in the
expression of Enpp1, Ank, and Alpl in intervertebral discs from ENT1-/- mice compared to
wild-type mice. Elevated plasma levels of inorganic pyrophosphate in ENT1-/- mice
indicated generalized disruption of pyrophosphate homeostasis. This is the first report of
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a role for ENT1 in regulating the calcification of soft tissues. Moreover, ENT1-/- mice
may be a useful model for investigating pathogenesis and evaluating therapeutics for the
prevention of mineralization in DISH and related disorders.

2.2 Introduction
Abnormal calcification of the extracellular matrix of soft connective tissues is
associated with a number of pathologies including vascular disease, chronic kidney
disease, and multiple skeletal disorders (1-4). Ossification of paraspinal ligaments is
often detected in middle-aged and elderly patients, presenting as one of two noninflammatory spondyloarthropathies: (1) diffuse idiopathic skeletal hyperostosis (DISH,
formerly referred to as Forestier disease (5)), which involves calcification of spinal
ligaments and extra-axial structures including entheses (4); and (2) ossification of the
posterior longitudinal ligament (OPLL), which is common in the Japanese population (6).
Although often misdiagnosed, DISH and OPLL are distinct from degenerative disc
disease, osteoarthritis, and ankylosing spondylitis (7).
DISH is typically diagnosed using radiographs of the thoracic spine or chest,
which demonstrate: (1) flowing calcifications along the anterolateral aspect of at least
four contiguous vertebral bodies; (2) preservation of intervertebral disc height (in contrast
to degenerative disc disease); and (3) absence of bony ankylosis of facet joints and
absence of sacroiliac erosion, sclerosis or fusion (in contrast to ankylosing spondylitis)
(8). DISH often manifests as back pain associated with limited range of spinal motion,
but can progress to the extent that lesions interfere with neighbouring structures,
including compression of the spinal cord and nerve roots (9,10). Lesions in DISH can
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also cause dysphagia (11), and DISH is associated with increased susceptibility to spinal
fractures (12) and postsurgical heterotopic ossifications (13). Correlative studies have
associated obesity, hypertension, diabetes mellitus, hyperinsulinemia, dyslipidemia,
elevated growth hormone levels, elevated insulin-like growth factor-1, and hyperuricemia
with DISH (14-16). It has been proposed that DISH lesions originate in fibrocartilaginous
structures including entheses (17); however, due to the lack of suitable animal models,
the underlying pathogenesis remains obscure.
Several factors including genetic background have been postulated to be involved
in the etiology of DISH; however to date no single gene defect has been associated with
the disease. In a subset of DISH patients of Asian descent, single-nucleotide
polymorphisms in the COL6A1 and FGF2 genes have recently been shown to confer
genetic susceptibility to DISH (18,19). In contrast to DISH, OPLL has been studied
extensively in the Japanese population, leading to identification of a number of associated
genes, including NPSS (20,21), COL11A (22), COL6A1(23), BMP2 (24), TGFβ (25), and
FGFR1 (19).
Recent advances point to a critical role for purine metabolism in the regulation of
biomineralization in diseases associated with either insufficient or ectopic mineralization
(26-31). For example, mutations in the gene encoding ectonucleotide pyrophosphatase/
phosphodiesterase 1 (ENPP1) have been associated with hypermineralization disorders
(26,27). Moreover, a recent study has linked ectopic arterial and joint calcifications with
loss of ecto-5'-nucleotidase (NT5E) function leading to decreased levels of extracellular
adenosine (28). To further explore the role of purine metabolism in the regulation of
biomineralization, we examined the phenotype of the mouse lacking the gene encoding
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the nucleoside transporter ENT1. ENT1 (equilibrative nucleoside transporter 1 or solute
carrier family 29 member 1, encoded by the Slc29a1 locus) is the predominant nucleoside
transporter expressed in mammalian cells (32). This sodium-independent, facilitative
diffusion carrier is responsible for the movement of hydrophilic nucleosides, such as
adenosine, across biological membranes. Loss of ENT1 activity would be expected to
modify extracellular adenosine levels, thus altering overall purine metabolism and
signaling through adenosine receptors. The present study reports the novel skeletal
phenotype of the ENT1-/- mouse that resembles DISH in humans.

2.3 Materials and Methods
2.3.1 Animals
ENT1-/- mice were generated through targeted deletion of exons 2 to 4 of the gene
encoding ENT1 by a cre-loxP targeting strategy (33). ENT1-/- mice were backcrossed
with C57BL/6 mice. The mouse colony was maintained through the breeding of
heterozygous animals (ENT1+/-) to obtain wild-type (ENT1+/+) and knockout (ENT1-/-)
littermates. Mice were housed in standard cages and maintained on a 12-hour light/dark
cycle, with rodent chow and water available ad libitum. Genotyping was performed as
described (34). Given the increased reported prevalence of DISH in males (25% of men
versus 15% of women over 50 years of age) (35), male mice were used for all
experiments. Mice were euthanized at the following ages: 1 month (4-4.5 weeks), 2
months (8-11 weeks), 4 months (16-18 weeks), 6 months (26-30 weeks) and 12+ months
(12-17 months). Experimental results were derived from groups of at least 3 wild-type
and 3 ENT1-/- mice. All aspects of this study were conducted in accordance with the
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policies and guidelines set forth by the Canadian Council on Animal Care and were
approved by the Animal Use Subcommittee of the University of Western Ontario,
London, ON, Canada.

2.3.2 Micro-computed tomography imaging
Micro-computed tomography (µCT) scanning, reconstruction and analysis were
performed based on reported protocols (36) with the following modifications. Formalinfixed or snap-frozen whole mice were imaged at Robarts Research Institute (London,
ON, Canada) using a dedicated laboratory µCT scanner (eXplore speCZT; GE Healthcare
Biosciences). Data were acquired with an X-ray tube voltage of 90 kV and a current of 40
mA. In one continuous rotation, 900 views were obtained at an angular increment of 0.4 o
and an exposure interval of 16 ms per view. The total scan time was 5 minutes per
animal. A calibrating phantom, consisting of a vial of water, air and a synthetic bonemimicking epoxy (SB3; Gammex Inc. Middleton, WI, USA), was imaged together with
the specimens. Images were acquired at isotropic voxel size of 100 m and reconstructed
into 3D images, using a modified cone-beam algorithm (37). The reconstructed data were
expressed in Hounsfield units by calibrating the gray-level values against those of water
and air. Mineralized tissue density within the volume of interest was expressed as
hydroxyapatite (HA) equivalent density (mg HA cm-3), based on the calibration provided
by the SB3 bone-mimicking material.
Images acquired for each animal were scored for severity of ectopic
mineralization, based on the percentage of affected sites within the spine (sites defined as
an intervertebral disc and/or associated paraspinal ligaments and entheses) in each
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anatomical region (cervical, thoracic, lumbar and caudal). Values ranged from 0 to 4,
with a score of 0 reflecting no detectable mineralized lesions, 1 indicating lesions
involving 0 to 30% of sites within the anatomical region, 2 indicating lesions involving
30 to 60% of sites, 3 indicating lesions involving 60 to 90% of sites and 4 indicating
lesions involving 90 to 100% of sites.

2.3.3 Measurement of mineralized tissue density
Using data acquired by µCT, quantification of the density and volume of
mineralized tissues was performed in a region of interest restricted to the spine (C1 to
sacrum), rib cage, and sternum. For this purpose, a 3D volume of interest was defined by
an operator within each volume image, using manually drawn contours lofted to create a
volume that included only the anatomy of interest (MicroView 2.2, GE Healthcare
Biosciences). Three measurements were obtained within this volume of interest: the
volume of hypermineralized tissue, the volume of tissue with density equivalent to that of
normal cortical bone, and the maximum density. Hypermineralized tissue was defined as
material that exceeded the maximum density of cortical bone in the spine of wild-type
mice within a specified age group. In the present study, we defined threshold values of
610, 630 and 710 mg HA cm-3 for maximum spinal bone density in animals of ages 2, 4
and 6 (or greater) months, respectively. Previous studies have reported a similar increase
in murine cortical bone density during the first 24 weeks of postnatal development (38).
Normal density tissue was defined as material that exceeded a minimum threshold (126
mg HA cm-3), but fell below the maximum thresholds defined above. Volume
measurements are reported in cubic millimeters (mm3), representing the summation of all
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the volume elements that fell within the defined range of mineral density. Additionally,
the maximum mineralized tissue density within the volume of interest was reported.
Nonlinear least squares fits were obtained using GraphPad Prism; data for volume of
hypermineralized lesions were fit with an exponential growth equation, and data for the
volume of normal bone and maximum density values were fit with one-phase association
equations.

2.3.4 Scanning electron microscopy and energy-dispersive X-ray spectroscopy
Scanning electron microscopy (SEM) imaging and energy-dispersive X-ray
spectroscopy (EDX) microanalyses were performed based on previous reports (39) using
a LEO 1540XB FIB/SEM instrument (Carl Zeiss, Oberkochen, Germany) and X-ray
analysis system (Oxford Instruments, Oxford, UK) at the Western Nanofabrication
Facility (The University of Western Ontario). Prior to SEM imaging, dried samples were
coated with 5 nm of osmium using a plasma coater (OPC-80T; Filgen Inc.). EDX spectra
were collected from bone and mineralized lesions identified by electron backscatter
imaging at 20 keV beam energy. Elemental analysis of the EDX spectra was performed
using INCA software (Oxford instruments), including background correction and fitting
of all peaks.

2.3.5 Histology
Formalin-fixed tissue samples were decalcified with Shandon TBD-2 Decalcifier
(Thermo Scientific, Nepean, ON Canada) at a ratio of 10:1 (fluid:tissue) for 5 days with
gentle rocking. Following standard histological processing, decalcified samples were
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embedded in paraffin and 5 µm-thick serial sections were cut. Tissues were sectioned in
the coronal plane, mounted on glass slides and baked for 48 hours at 45°C. Slides were
stained with haematoxylin and eosin (H&E) and images were acquired using a Leica
DM1000 microscope.
For visualization of cell nuclei, sections described above were dewaxed in xylene
and rehydrated by successive immersion in descending concentrations of ethanol.
Mounting was performed with VECTASHIELD Mounting Medium with 4',6-diamidino2-phenylindole (DAPI) (Burlingame, CA) and images were captured using a Leica
DMI6000B microscope.

2.3.6 Blood chemistry
High-performance liquid chromatography (HPLC) was used to analyze plasma for
levels of adenosine and adenosine metabolites to determine the functional consequence of
loss of ENT1. At 2 months of age, mice were anesthetized with pentobarbital. Blood was
collected by cardiac puncture into a syringe containing NaCl (118 mM), KCl (5 mM),
EDTA (13.2 mM), 5-iodotubercidin (10 µM) to inhibit adenosine kinase, erythro-9-(2hydroxy-3-nonyl)adenine hydrochloride (EHNA, 100 µM) to inhibit adenosine
deaminase and dilazep (10 µM) to inhibit adenosine transport (40). Plasma was isolated
by sedimentation at 3,000g for 10 minutes at 4°C. Plasma was applied to a 10-kDa cutoff
ultra-filtration column and sedimented at 14,000g for 15 minutes at 4°C. Filtered plasma
was analyzed on an Onyx monolithic C18 column as described (41), using a Hewlett
Packard 1090 LC with UV detector. Adenosine was detected at 260 nm and adenosine
metabolites at 250 nm.
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To screen for systemic changes resulting from loss of ENT1 function, serum
chemistry was performed using established panels of clinical chemistry parameters. At 2
months of age, mice were anesthetized with pentobarbital and blood was collected by
cardiac puncture. Blood was allowed to coagulate at room temperature for 30 minutes.
Samples were then sedimented at 3,000g for 10 minutes at 4°C and the serum supernatant
was transferred to a fresh tube and frozen at -80°C. Chemical and biochemical analyses
were performed by the Centre for Modeling Human Disease at the Toronto Centre for
Phenogenomics (Toronto, Canada).
To assay plasma levels of inorganic pyrophosphate (PPi), mice were anesthetized
with pentobarbital and blood was collected by cardiac puncture. Samples were transferred
to microfuge tubes containing heparin (5 USP units/mL of blood) and plasma was
isolated by sedimentation at 3,000g for 10 minutes at 4°C. Plasma was applied to 10-kDa
cutoff ultra-filtration spin columns and sedimented at 14,000g for 20 minutes at 4ºC. A
fluorometric PPi assay kit (ab112155; Abcam, Cambridge, MA, USA) was first validated
using plasma samples from wild-type mice, plasma supplemented with a saturating
concentration of PPi (30 µM) in the presence or absence of inorganic pyrophosphatase
(0.0012 units/µL sample; Sigma) (Fig. 2.1). Plasma samples were isolated from 2-monthold wild-type and ENT1-/- mice (n=6 mice for each genotype) and analyzed according to
the manufacturer’s protocol with an incubation time of 20 minutes. Fluorescence was
measured at excitation and emission wavelength of 316 and 456 nm, respectively, using a
SpectraMax M5 microplate reader (Molecular Devices) with Softmax Pro v5 software.
Values were interpolated using linear regression. Background levels of plasma
autofluorescence were negligible.
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Figure 2.1: Validation of inorganic pyrophosphate assay.
The fluorometric Pyrophosphate Assay Kit was validated using pooled plasma obtained
from wild-type mice. To reduce protein concentration, plasma was applied to a 10 kDa
cutoff ultra-filtration columns. Pyrophosphate was measured in: i) filtered plasma; ii)
filtered plasma supplemented with a saturating concentration of exogenous
pyrophosphate (PPi, 30 µM); and iii) filtered plasma supplemented with PPi (30 µM) and
pyrophosphatase (PPase, 0.0012 units/µL sample). Samples were analyzed according to
the manufacturer’s protocol with an incubation time of 20 min. Exogenous
pyrophosphate caused a significant increase in the signal (to maximal detectable levels).
Moreover, incubation with pyrophosphatase significantly diminished the pyrophosphateinduced increase in signal intensity. Taken together, these data establish that the kit
effectively detects pyrophosphate in ultra-filtered plasma. Assay was performed using 4
replicate samples for each condition. Data are presented as means ± SEM, n=4. Bars
labeled with the same lower case letter are not significantly different, based on one-way
analysis of variance followed by a Tukey multiple comparisons test.
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2.3.7 Quantitative real-time RT-PCR
At 6 months of age, littermate-paired wild-type and ENT1-/- mice (n=8 for each
genotype) were dissected to isolate intervertebral discs (IVDs) inclusive of annulus
fibrosus, nucleus pulposus, and cartilage endplates. IVDs from each animal were
separated according to anatomical location as cervical-thoracic, lumbar, or caudal.
Tissues were placed directly in 1 mL of TRIzol Reagent (Life Technologies, Wilmington,
DE) and homogenized using a PRO250 Polytron benchtop homogenizer (PRO Scientific,
Oxford, CT). Total RNA was extracted according to the manufacturer’s protocol and
quantified using a NanoDrop 2000 spectrophotometer (Thermo Scientific, Mississauga,
ON). For each sample, 1 µg RNA was reverse transcribed into cDNA using Superscript II
Reverse Transcriptase (Life Technologies). Gene expression patterns were determined by
real-time PCR using the Bio-Rad CFX384 system. PCR reactions were run in triplicate,
using 25 µM forward and reverse primers (primer sequences in Table 2.1) with 2X
SsoFast EvaGreen Supermix (Bio-Rad, Mississauga, ON). The PCR program consisted
of the following: initial 3 min at 95oC for denaturing; 95oC for 10 s denaturing; 30 s
annealing/elongation (temperatures provided in Table 2.1), for a total of 40 cycles. Gene
transcript levels were determined relative to a six-point calibration curve made from
cDNA generated from heart, brain, kidney, muscle, intervertebral disc, and calvarial
RNA (from wild-type mice). The starting concentration of the cDNA standard (83 – 136
ng/µl) was inputted into the Bio-Rad CFX Manager 2.0 software to generate the standard
curve (1/5 serial dilution). Values for gene transcript levels are expressed relative to the
calibration curve in ng/µl. Standard curves were generated to control for primer
efficiency and specificity of primers was determined by melt curve analysis (0.5C/5 s).
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Table 2.1: Real-time PCR Primer Sequences
Gene Name

Adora3
Ank
Alpl
Enpp1
ENT1

Primer Sequence (5’ to 3’)

Optimal
Temperature (oC)

Fwd – ACTTCTATGCCTGCCTTTTCATGT
Rev – AACCGTTCTATATCTGACTGTCAGCTT
Fwd – CCCTGATAGCCTACAGTGACTTAGG
Rev – GAAGGCAGCGAGATACAGGAA
Fwd - CCAACTCTTTTGTGCCAGAGAA
Rev – GGCTACATTGGTGTTGAGCTTTT
Fwd - CAAAACCCACAATGACTGTTGC
Rev – CTGGACACTCCGGGGTATCG
Fwd - CAAGTATTTCACAAACCGCCTGGAC
Rev – GAAACGAGTTGAGGCAGGTGAAGAC
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2.4 Results
2.4.1 Ectopic mineralization in ENT1-/- mice
Previous studies reported that ENT1-/- mice are phenotypically normal, with only
a modest decrease (~10%) in body weight compared with that of wild-type littermates
(33). At young ages, open-field locomotor activity in ENT1-/- and wild-type mice does not
differ. Moreover, there is no significant difference in spontaneous mortality rates up to 6
months of age. To date, there have been no reports of phenotypic changes in skeletal
tissues related to mineralization (33,34,42,43); however, all reported studies were
conducted on mice less than 4 months of age.
In the present study, we noted that the spines of 6-month-old ENT1-/- mice were
extremely rigid. At 8 months, ENT1-/- mice demonstrated decreased hind limb mobility
that progressed to hind limb paralysis by 12 to 17 months of age. Postmortem analysis of
a 17-month-old ENT1-/- mouse revealed hard, chalky white lesions protruding ventrally
from the thoracic spine (Fig. 2.2A). µCT images revealed large radio-opaque lesions at
distinct foci in the cervical and upper thoracic regions of ENT1-/- mice, localized to
paraspinal and intervertebral tissues and protruding in some cases into the spinal canal
(Fig. 2.2B). Histological examination identified large accumulations of amorphous
material (Fig. 2.2C) localized to the intervertebral discs (upper panel) and paraspinal
tissues associated with the spinous processes (lower panel). The presence of calcified
lesions within the spinal canal, impinging on the spinal cord, was consistent with the
decreased mobility and paralysis observed in ENT1-/- mice.
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Figure 2.2: Ectopic mineralization of spinal tissues in ENT1-/- mice.
(A) Gross appearance of ventral aspect of the thoracic spine from 17-month-old wild-type
(WT) and ENT1-/- mice. Mineralized lesions protrude from intervertebral spaces,
associated with rib entheses. Lesions demonstrated hard, chalky consistency and were
whitish in colour. (B) Maximum intensity projection of µCT images showing the lateral
aspect of the cervical and thoracic spine of 17-month-old WT and ENT1-/- mice. Ectopic
radio-opaque material is evident in paraspinal and intervertebral regions of the spine
(arrows) extending into the spinal canal (SC). (C) Histological sections of decalcified
spinal tissues from 17-month-old ENT1-/- mouse (spinal column and spinal cord) stained
with H&E. Mineralized lesion (outlined in black) can be seen protruding into the spinal
canal and impinging on the spinal cord. Images in B and C are oriented with ventral to the
left. Scale bars represent 200 μm.
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2.4.2 Time course of phenotype development
µCT imaging was employed to assess the development and extent of ectopic
mineralization in ENT1-/- mice over time (Fig. 2.3A). Images were scored for severity,
based on the percentage of affected sites within the spine (intervertebral discs, and
associated paraspinal ligaments and entheses) in each anatomical region (Fig. 2.3B).
Ectopic mineralization of spinal tissues was not evident in wild-type animals at any time
point (Fig. 2.3A), or in ENT1-/- mice at 1 month of age (not shown).
Ectopic mineralization in ENT1-/- mice proceeded temporally in a consistent
anatomical pattern. At 2 months of age, maximum intensity projection (MIP) images
revealed radio-opaque material in the paraspinal tissues of the cervical spine and the rib
entheses of the upper thoracic spine (Fig. 2.3, top panels). At this age, there was no
detectable involvement of intervertebral discs.
With advancing age, accumulation of ectopic mineral progressed caudally, with
involvement of the lumbar spine at 6 months (Fig. 2.3, middle panels). In addition to
paraspinal tissues and rib entheses, lesions were observed within the intervertebral spaces
at 6 months in both the thoracic and lumbar spine. At this time point, lesions involved 60
to 90% of the cervical spine and 30 to 60% of the thoracic spine. Interestingly, lesions did
not progress caudally in a uniform manner. Following involvement of the cervical and
upper thoracic spine, lesion formation initially bypassed the mid-region of the thoracic
spine and first appeared specifically in thoracic vertebrae T11-T12 (Fig. 2.3A, asterisk). At
greater ages, lesions developed in the intervening mid-region of the thoracic spine.
By 12 months of age, ectopic mineralization was detected in >60% of the
cervical, thoracic and lumbar regions of the spine, as well as >30% of intervertebral discs
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Figure 2.3: Temporal progression of ectopic mineralization in ENT1-/- mice.
(A) Lateral and antero-posterior maximum intensity projections of micro-CT images of
wild-type (WT) and ENT1-/- mice at 2, 6 or 12+ months of age. Ectopic radio-opaque
material was observed in paraspinal tissues of the cervical spine at 2 months of age (top
panel, white arrows). By 6 months of age, lesions were detected in the cervical (white
arrows), thoracic and lumbar spine in paraspinal ligaments, rib entheses and
intervertebral discs (middle panel). At 6 months, lesions involved the upper thoracic
spine, but appeared to bypass the mid-region of the thoracic spine to specifically affect
sites in the vicinity of thoracic vertebrae T11-T12 (indicated by white asterisk). By 12
months of age, lesions involved virtually the entire cervical, thoracic and lumbar spine,
and were detectable in the intervertebral discs of the caudal spine (lower panel). Note that
the focal hyperintensities observed in the abdomen result from high-density material in
the animal chow; these bright spots do not represent ectopic calcifications. (B) The
percentage of sites affected by mineralization in each anatomical region of the spine was
scored in ENT1-/- mice at 2, 6 or 12+ months of age. A severity score of 0 reflects no
detectable mineralized lesions, 1 indicates lesions involving 0 to 30% of sites within the
anatomical region, 2 indicates lesions involving 30 to 60% of sites, 3 indicates lesions
involving 60 to 90% of sites, and a score of 4 indicates lesions involving 90 to 100% of
sites. The symbols represent scores for individual mice and bars represent the mean.
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of the caudal spine (Fig. 2.3, lower panel). In addition, there was notable decrease in
kyphosis between 6 and 12 months of age in ENT1-/- mice compared to wild-type (Fig.
2.3A, lower panel). No evidence of ectopic mineralization was detected in the vasculature
of ENT1-/- mice at any time point examined by µCT.
To examine the consequence of ENT1 haploinsufficiency, 6-month-old
heterozygous ENT1+/- mice were examined by µCT (Fig. 2.4). In contrast to ENT1-/mice, heterozygous animals did not demonstrate ectopic mineral formation in paraspinal
tissues, rib entheses, or intervertebral discs. Moreover, the loss of kyphosis observed in
knockout animals was not apparent; ENT1 heterozygous animals were indistinguishable
from wild- type controls.

2.4.3 Density and elemental composition of ectopic lesions
Mineralized tissue density of wild-type and ENT1-/- mice at different ages was
quantified from µCT data. The region of interest for these analyses consisted of the
cervical to lumbar spine, rib cage, and sternum. Hypermineralized tissue was detected in
paraspinal and intervertebral tissues of the spine, as well as the sternocostal articulations
(highlighted in red in Fig. 2.5A). Quantification revealed that the volume of
hypermineralized tissue grew exponentially with age in the ENT1-/- mice, whereas there
was little hypermineralized tissue detectable in wild-type mice at any age (Fig. 2.5B).
We also quantified the volume of mineralized tissue with density equivalent to that of
normal cortical bone (Fig. 2.5C). Whereas the wild-type animals appeared to reach a
plateau of approximately 355 mm3 by day 200 (reflecting bone growth), ENT1-/- mice
reached a plateau of 552 mm3 by day 400 (reflecting both bone growth and accumulation
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Figure 2.4: Micro-CT images of wild-type, heterozygous, and ENT1-/- mice.
Images are lateral (top panel) and antero-posterior (bottom panel) maximum intensity
projections of wild-type (WT), heterozygous (ENT1+/-), and ENT1-/- mice at 6 months of
age. No ectopic mineral was observed in the WT or heterozygous mice. Ectopic radioopaque material was observed in ENT1-/- mice; lesions were detected in the paraspinal
ligaments, rib entheses and intervertebral discs of the cervical, thoracic, and lumbar
regions (white arrows). Images are representative of 3 animals of each genotype.
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Figure 2.5: Quantification of the volume and density of mineralized material in
wild-type and ENT1-/- mice over time.
(A) Lateral maximum intensity projections of the µCT images of a wild-type (WT) and
an ENT1-/- mouse at 17 months of age. The region of interest for these analyses was
restricted to the cervical, thoracic and lumbar spine, rib cage and sternum. The regions
highlighted in red represent hypermineralized tissue within the region of interest. (B) The
volume of hypermineralized tissue grew exponentially with age in the ENT1-/- mice. (C)
ENT1-/- mice also showed increased volume of mineralized tissue with normal bone
density (consisting of both bone and ectopic calcifications). Whereas the wild-type
animals appeared to reach a plateau (of approximately 355 mm3 by day 200), the ENT1-/mice reached a plateau (552 mm3) by day 400. (D) Likewise, the maximum mineral
density of the wild-type mice reached a plateau before an age of 200 days, whereas that
of the ENT1-/- mice continued to increase past day 400. For B-D, the symbols represent
µCT-derived parameters for individual mice and the lines represent the non-linear fits.
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of ectopic mineral). Likewise, the maximum mineral density of the wild-type mice
reached a plateau before an age of 200 days, whereas that of the ENT1-/- mice continued
to increase past day 400 (Fig. 2.5D), reflecting hypermineralization of the ectopic lesions.
A summary and statistical analysis of these data is presented in Table 2.2. From 2
to 17 months of age, the volume of bone in wild-type mice increased from 259 to 356
mm3 with only about 0.5 mm3 appearing hypermineralized (regardless of age) according
to the thresholds used. The mineralized tissue volume of ENT1-/- mice was similar to that
of wild-type controls up to 6 months of age. In contrast, 12-to 17-month-old ENT1-/- mice
had a significantly greater volume of mineralized tissue than the equivalent age of wildtype mice (527 versus 356 mm3). In addition, the ENT1-/- mice had a significantly greater
volume of hypermineralized tissue than wild-type mice between 12 to 17 months old (16
versus 0.5 mm3), and the maximum mineral density was significantly greater in ENT1-/mice than wild-type controls at both 6 and 12 month of age. Note that, whereas the
maximum mineral density observed in ENT1-/- mice (1044 mg HA cm-3) does not exceed
the typical value for fully mineralized cortical bone (approximately 1050 mg HA cm -3), it
is significantly greater than the mineral density of cortical bone observed in the spine of
wild-type littermates (744 mg HA cm-3).
Samples from wild-type and ENT1-/- mice at 6 months of age were analyzed by
EDX to determine the elemental content of both cortical bone and mineralized lesions.
Mineralized lesions appeared by SEM as a disordered amorphous material (Fig. 2.6A, B)
and EDX revealed a high content of calcium and phosphorus (Fig. 2.6C).The mean
elemental content of bone and lesions is displayed as percent atomic ratio in Table 2.3.
The vertebral bone from ENT1-/- mice was not significantly different from that of wild-
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Table 2.2: Mineralized Tissue Density in ENT1-/- and Wild-type Mice

µCT-derived values for the volume of normal and hypermineralized tissue and the
maximum density in ENT1-/- and wild-type mice. Data are means ± SD. Differences were
evaluated by two-way analysis of variance (ANOVA) followed by a Bonferroni multiple
comparison test.
ENT1 = equilibrative nucleoside transporter 1; HA = hydroxyapatite.
Significantly different from wild type: * p < 0.05, ** p < 0.001.
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Figure 2.6: Scanning electron microscopy (SEM) and elemental analysis of
mineralized lesions by energy dispersive X-ray spectroscopy (EDX).
(A, B) SEM of mineralized lesion in ENT1-/- mouse at 6 months of age. Mineralized
lesions appeared as a disordered amorphous material. Representative areas (2 or 3 per
sample) were selected and probed by EDX for calcium (Ca), phosphorous (P), carbon (C)
and oxygen (O). Magnesium (Mg) and sodium (Na) were detected in some, but not all,
samples and hence were not included in the quantitative analysis shown in Table 2.3.
(C) A representative EDX spectrum (from the region highlighted in Panel A) is shown,
revealing a high content of calcium and phosphorus. Images and spectrum are
representative of lesion samples from 4 mice.
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Table 2.3: Energy-Dispersive X-ray Spectroscopy
% Atomic Ratio
Location Genotype
Vertebra

Lesion

Carbon

Oxygen

Phosphorous

Calcium

Ca/P Ratio

WT

45.1 ± 4.8 34.0 ± 1.8

7.4 ± 0.7

12.7 ± 2.3

1.7 ± 0.1

ENT1-/-

45.6 ± 2.2 37.5 ± 0.9

6.8 ± 0.5

10.5 ± 0.6

1.6 ± 0.1

ENT1-/-

37.6 ± 3.5 41.6 ± 2.3

8.7 ± 0.4*

13.3 ± 1.1*

1.5 ± 0.1

Scanning electron microscopy was used to identify regions of vertebral cortical bone and
ectopic mineralization (lesion) in samples isolated from 6-month-old WT and ENT1-/mice. Energy-dispersive X-ray spectroscopy was then applied to these selected regions to
obtain the % atomic ratios of the indicated elements. Data are mean ± SEM, n = 4.
WT = wild-type; ENT1 = equilibrative nucleoside transporter 1.
* Significant difference between lesion and ENT1-/- vertebra (p < 0.05; Student’s t-test).
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type mice in terms of elemental ratios. In contrast, ectopic mineralized lesions in ENT1-/mice displayed higher levels of phosphorus and calcium relative to vertebral bone,
consistent with the greater mineralized tissue density observed using µCT. The
calcium/phosphorus ratio was similar in all samples.

2.4.4 Histological appearance of mineralized lesions
We first assessed the intervertebral disc regions of wild-type and ENT1-/- mice
between 12 and 17 months of age. Decalcified sections stained with H&E revealed the
presence in ENT1-/- mice of large accumulations of amorphous, eosinophilic acellular
material suggestive of niduses of mineralization in the cervical, thoracic, lumbar and
caudal regions (Fig. 2.7). Interestingly, within the intervertebral disc, lesions appeared to
be localized within the annulus fibrosus, leading to lateral compression of the nucleus
pulposus and extensive bulging of the annulus fibrosus out of the intervertebral space
(Fig. 2.7, right panels). There was no evidence that lesions were associated with
inflammation or increased vascularization. Since the sacral intervertebral discs undergo
progressive fusion with the onset of skeletal maturity in mice, this region was not
examined for ectopic mineralization.
Lesions were also detected in the sternocostal region of ENT1-/- mice between 12
and 17 months of age, by both µCT and histology (Figs. 2.3, 2.5A and Fig. 2.8A). In this
region, extensive ectopic mineral was detected within the connective tissue of the
sternocostal articulations, leading to deformation of the sternum. In contrast, examination
of appendicular joints revealed no aberrant morphology or evidence of ectopic
mineralization (Fig. 2.8B-E) establishing that lesions are specifically associated with the
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Figure 2.7: Histological appearance of spinal tissues in cervical (A), thoracic (B),
lumbar (C) and caudal (D) spines of 12+ month old wild-type (WT) and ENT1-/mice.
Vertebral structures are indicated in panel A: the intervertebral disc (IVD) is formed by
the annulus fibrosus outlined in yellow and nucleus pulposus outlined in red, which are
located between adjacent vertebral bones (VB). The spines of ENT1-/- mice show
irregular lesions within the annulus fibrosus of the intervertebral disc. Lesions are
encapsulated by layers of fibrocartilaginous cells. Lesions are outlined with black dashed
lines and are shown at higher magnification in the panels to the right. Samples were
sectioned in the coronal plane and stained with haematoxylin and eosin (H&E). Images
are oriented with rostral at the top and are representative of 3 animals of each genotype
12-17 months of age. Scale bars represent 200 μm.
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Figure 2.8: Histological appearance of sternocostal (A), humeroulnar (B),
tibiofemoral (C), radiocarpal (D) and talocrural (E) joints in 12+ month-old wildtype (WT) and ENT1-/- mice (arrows indicate joint spaces).
In ENT1-/- mice, sternocostal joints displayed lesions in fibrocartilaginous connective
tissues, similar to those seen in the spine. In contrast, the appendicular joints appeared to
be unaffected. Lesion in panel A is outlined with black dashed line and tissues are shown
at higher magnification in the panel to the right. Samples were sectioned in the coronal
plane and stained with haematoxylin and eosin (H&E). Images are representative of 3
animals of each genotype 12-17 months of age. Scale bars represent 200 μm.
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axial skeleton.
Comparison of histological sections of spinal tissues from wild-type and ENT1-/mice at 6 months of age revealed further insights into the development of lesions. Within
the cervical spine of 6-month-old ENT1-/- mice, large lesions were associated with the
paraspinal ligaments, but no distinct lesions were detected within the intervertebral discs
in this region (Fig. 2.9A). However, the outer annulus fibrosus of the intervertebral discs
did appear altered, with regions of metaplasia and disruption of normal tissue architecture
(Fig. 2.9A, arrowhead). Within the thoracic spine of 6-month-old ENT1-/- mice, extensive
lesions were localized within: (1) the annulus fibrosus; (2) the fibrocartilaginous tissue of
the posterior paraspinal ligaments; and (3) the fibrocartilaginous tissue of the rib entheses
(Fig. 2.9B). In the lumbar spine of 6-month-old ENT1-/- mice, small lesions were detected
within the annulus fibrosus, leading to disruption of intervertebral disc structure and
displacement of the nucleus pulposus (Fig. 2.9C). At this time point, no changes were
detected within the caudal spine.
At 2 months of age, when ectopic mineral was first detected in ENT1-/- mice by
µCT, histological examination also demonstrated lesions within the paraspinal ligaments
of the cervical spine (Fig. 2.10A). Interestingly, these lesions were associated with large
regions of metaplasia, with a disruption of normal tissue architecture and increased
cellularity (Fig 2.10A, arrowheads). In the upper thoracic spine, the mineralized lesions
detected by µCT in ENT1-/- mice were localized to the fibrocartilaginous structures of the
paraspinal ligaments and rib entheses, within larger regions demonstrating evidence of
hyperplasia and desmoplasia (Fig. 2.10B, arrowheads). At this time point, no lesions were
detectable in intervertebral discs within any region of the spine. Early lesions evident at 2
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Figure 2.9: Histological appearance of spinal tissues in cervical (A), thoracic (B) and
lumbar (C) spine segments from 6-month-old wild-type (WT) and ENT1-/- mice.
Representative images demonstrate the location of lesions consisting of irregular
accumulations of eosinophilic material in the intervertebral disc (IVD), paraspinal
ligaments, and rib entheses in ENT1-/- mice. Lesions are outlined with black dashed lines
and tissues are shown at higher magnification in the panels to the right. Arrowhead in (A)
indicates a nonmineralized region of metaplasia accompanied by disruption of normal
tissue architecture in the annulus fibrosus of the IVD. Images are oriented with rostral at
the top and are representative of 3 animals of each genotype. Scale bars represent 200
μm.
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Figure 2.10: Histological appearance of the intervertebral disc (IVD), paraspinal
ligaments, and rib entheses in cervical (A) and thoracic (B) spine segments from 2month-old wild-type (WT) and ENT1-/- mice. Lesions are outlined with black dashed
lines and tissues are shown at higher magnification in the panels to the right. Arrowheads
indicate regions demonstrating tissue metaplasia. (C) Serial sections of representative
lesion localized to the paraspinal tissue of the thoracic spine of a 2-month-old ENT1-/mouse stained with H&E (top panel) and DAPI (bottom panel). Cells with eosinophilic
nuclei are detected in the transition zone (TZ) between normal fibrocartilaginous tissues
and lesion. DAPI staining demonstrates that these cells retain an intact nuclear structure
(arrows indicate individual cells). Images are oriented with rostral at the top and are
representative of at least 3 ENT1-/- animals. Scale bars represent 200 μm.
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months of age were surrounded by a clearly demarcated transition zone (TZ; Fig. 2.10C).
The periphery of this zone consisted of typical fibrocartilaginous tissue and, as expected,
cells with basophilic nuclei that stained positively with DAPI (Fig. 2.10C, lower panels).
However, the more central region of the transition zone was characterized by metaplasia,
with cells displaying eosinophilic nuclei that stained positively with DAPI, revealing an
intact nuclear structure. The TZ surrounded the presumptive mineralized lesion, which
contained large accumulations of amorphous matrix and necrotic cell debris. There was
no evidence of apoptotic nuclei within the lesion or TZ.

2.4.5. Differences in blood chemistry and gene expression associated with the
ENT1-/- phenotype
Blood plasma or serum from 2-month-old wild-type and ENT1-/- mice was
analyzed for components related to mineralization as well as adenosine and adenosine
metabolites (Table 2.4). HPLC analysis of plasma showed 2.8-fold greater adenosine
levels in ENT1-/- than wild-type mice. In contrast, there were no significant differences in
levels of the adenosine metabolites xanthine and uric acid, arguing against the possibility
that ectopic lesions involved deposition of monosodium urate crystals. Importantly,
serum levels of alkaline phosphatase, calcium, phosphate, and magnesium were not
significantly different in ENT1-/- and wild-type mice. On the other hand, quantification of
plasma PPi levels revealed 3.4 ± 1.0-fold greater levels in ENT1-/- mice than in wild-type
controls (n=6 two-month-old mice for each genotype, p < 0.05).
Given this alteration in PPi levels, we interrogated the expression of genes
associated with pyrophosphate metabolism in intervertebral disc tissues isolated from
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Table 2.4: Blood Chemistry
Wild-type

ENT1-/-

(n = 4)

(n = 5)

Adenosine (µM)

2.2 ± 0.4

6.2 ± 1.4*

Xanthine (µM)

4.3 ± 1.5

5.2 ± 2.4

Uric acid (µM)

163 ± 23

176 ± 14

97 ± 9

109 ± 10

ALP (IU/L)
Ca (mM)

2.30 ± 0.03 2.31 ± 0.02

Mg (mM)

1.26 ± 0.04 1.30 ± 0.08

Pi (mM)

3.1 ± 0.3

3.7 ± 0.4

Data are means ± SEM. Serum was obtained
from wild-type and ENT1-/- mice at two
months of age.
ALP = total alkaline phosphatase; ENT1 =
equilibrative nucleoside transporter 1; Pi =
inorganic phosphate.
* Significantly different from wild-type (p <
0.05, Student’s t-test).
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Figure 2.11: Gene expression analysis of intervertebral disc tissues isolated from 6month-old wild-type and ENT1-/- mice.
Real-time PCR analysis of genes associated with PPi metabolism and tissue
mineralization revealed significant reductions in the expression of (A) Enpp1, (B) Ank,
and (C) Alpl in ENT1-/- mice compared to wild-type controls. (D) In contrast, there was
no significant difference in the expression of the adenosine A3 receptor (Adora3),
indicating specificity of changes in gene expression. (E) Real-time PCR analysis of ENT1
expression revealed no significant differences between anatomical regions of the spine in
wild-type mice. ** Significantly different from wild-type (p < 0.01, Student’s t-test).
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ENT1-/- and wild-type littermate control mice at 6 months of age. Real-time PCR analysis
demonstrated a significant decrease in the expression of ectonucleotide pyrophosphatase/
phosphodiesterase 1 (Enpp1; Fig. 2.11A), Ank (a putative PPi transporter) (Fig. 2.11B),
and tissue nonspecific alkaline phosphatase (Alpl; Fig. 2.11C) in ENT1-/- mice. In
contrast, no significant difference was detected in the expression of unrelated genes
including the adenosine A3 receptor (Adora3; Fig. 2.11D) in ENT1-/- and wild-type mice,
indicating specificity.
To determine if the specific anatomical pattern of ectopic mineralization was
influenced by endogenous levels of ENT1, expression was assessed in 6-month-old wildtype mice. No differences were detected in ENT1 transcript levels in intervertebral disc
tissues isolated from cervical-thoracic, lumbar, or caudal regions of the spinal column
(Fig. 2.11E).

2.5 Discussion
This is the first report of a role for ENT1 in regulating biomineralization. We
discovered that ENT1-/- mice develop ectopic mineralization with distribution restricted to
the fibrous connective tissues of the spine and sternum. In the spine, pathological
mineralization begins in the paraspinal fibrocartilaginous tissues and progresses to
involve the annulus fibrosus of intervertebral discs. Aberrant mineralization is first
observed in ENT1-/- mice between 6 and 8 weeks of age in the paraspinal connective
tissues of the cervical vertebrae. With advancing age, lesions increase in severity and
progress to other regions of the spine, with ectopic mineralization eventually involving
the thoracic, lumbar and caudal spine, as well as the sternocostal articulations.
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ENT1-/- mice were first used to investigate the role of adenosine transport in the
central nervous system pathways regulating alcohol consumption (33). In that study, male
mice were examined at approximately 10 weeks of age and appeared normal in their
anatomy, physiology, mortality rates and consumption of water. However, ENT1-/- mice
consumed twice as much alcohol compared to wild-type controls. This behavior was
associated with a decrease in endogenous adenosine tone, which was not due to loss of A1
receptors or decreases in A1 receptor affinity. ENT1-/- mice have also been shown to
exhibit reduced anxiety-like behaviors (44). Levels of endogenous extracellular
adenosine were not reported in these studies.
More recently, ENT1-null mice have been used to investigate the role of this
transporter in the cardiovascular system. Microvascular endothelial cells isolated from
ENT1-/- mice have enhanced expression of the A2A adenosine receptor and adenosine
deaminase (34). Cardiomyocytes and microvascular endothelial cells from ENT1-/- mice
are relatively resistant to ischemic insult and ENT1-/- mice show decreased heart damage
in response to ischemia and hypoxia (45). Furthermore, loss of ENT1 protects against
ischemic acute kidney injury through control of postischemic renal perfusion (46).
Overall, these studies point to a cardioprotective role of ENT1. However, it is unlikely
that changes in the nervous and cardiovascular systems give rise to ectopic mineralization
in ENT1-/- mice, especially of the inner annulus fibrosus, which is considered an
avascular and aneural tissue (47,48).
In the present study, we found that plasma adenosine concentrations are
significantly elevated in the ENT1-/- mice compared to wild-type littermates. This finding
is in keeping with differences reported (42). The greater plasma concentration of
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adenosine in ENT1-/- mice likely reflects extracellular accumulation of adenosine due to
lack of uptake by cells that normally express ENT1, one of the primary uptake pathways
for adenosine (32,49). The role of elevated extracellular adenosine in the formation of
abnormal mineral deposits in fibrocartilaginous tissues remains to be explored, but may
involve local changes in adenosine receptor signaling.
In this regard, recent advances point to a critical role for purine metabolism and
signaling in the regulation of biomineralization and in diseases associated with either
insufficient or ectopic mineralization (26-31). Once released by the cell, extracellular
adenosine triphosphate (ATP) is sequentially metabolised by cell-surface enzymes,
leading first to the production of PPi and adenosine monophosphate (AMP), which in turn
are converted to inorganic phosphate and adenosine. Ectonucleotide pyrophosphatase/
phosphodiesterase 1 (Enpp1) is responsible for the first step in this process, and the
release of PPi has been shown to inhibit ectopic calcification in soft tissues (50).
Interestingly, we show that ENT1-null mice demonstrate significant downregulation of
Enpp1 expression in intervertebral disc tissues relative to wild-type littermate controls.
These findings are in keeping with the reported association between mutations in the
gene encoding Enpp1 and hypermineralization disorders such as idiopathic infantile
calcification (26) and OPLL (27). Furthermore, Enpp1-/- mice display soft tissue
mineralization in the Achilles tendon, paraspinal ligaments and intervertebral discs, as
well as hyperostosis of peripheral joints and calcification of articular cartilage (51).
However, elements of the appendicular skeleton are not affected in ENT1-/- mice; changes
are limited to fibrocartilaginous tissues of the axial skeleton.
We also observed a significant decrease in Ank expression in the intervertebral
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discs of ENT1-/- mice. Ank is a transmembrane protein that is thought to mediate PPi
transport. In mice, loss-of-function mutations of Ank lead to arthritis, ectopic crystal
formation and generalized joint fusion (52), whereas, in humans, dominant mutations are
associated with craniometaphyseal dysplasia (53,54) and familial chondrocalcinosis
(55,56). Thus, like Enpp1, decreased Ank expression in the spinal tissues of ENT1-/- mice
would be expected to further suppress extracellular PPi levels, permitting the formation of
ectopic mineral deposits.
Unexpectedly, expression of Alpl was also found to be decreased in the
intervertebral discs of ENT1-null mice. Alpl encodes tissue-nonspecific alkaline
phosphatase, which is responsible for the hydrolysis PPi (51), and Alpl expression has
been shown previously to be regulated by extracellular adenosine (28). In humans,
disruption

of

ALPL

causes

hypophosphatasia,

characterized

by

skeletal

hypomineralization (57) and presumably a result of excessive accumulation of PPi. Thus,
decreased Alpl expression in the spinal tissues of ENT1-/- mice would be expected to
increase extracellular PPi levels, counteracting the decrease in PPi arising from changes in
Enpp1 and Ank expression. Moreover, it is conceivable that a generalized decrease in
Alpl expression could account for the increase in plasma PPi that we observed in ENT1-/mice.
Adenosine and ATP can regulate cell behaviour and gene expression through cell
surface receptors – the adenosine receptor family (58) and the P2 family of nucleotide
receptors (59,60), respectively. Adenosine increases intracellular cyclic AMP (cAMP)
levels via its A2A and A2B receptor subtypes. cAMP has been shown to induce abnormal
calcification of vascular smooth muscle cells via a mechanism involving reduction in
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extracellular PPi accumulation (61,62). In addition, activation of the P2X7 subtype of
ATP receptors promotes bone formation and mineralization (27,63).
Taken together, our data suggest that disruption of adenosine signaling and PPi
metabolism in ENT1-/- mice is associated with disease onset and progression. Although
there are no reported associations between mutations in the gene encoding ENT1 in
humans and DISH, the high incidence of this disease in the human population argues
against an underlying single gene defect. However, disruption of adenosine or PPi
metabolism could result from alterations in the function of one or more regulatory or
metabolic proteins – either through genetic defects or as a consequence of cell aging.
In ENT1-/- mice, the only location outside of the spine that exhibited ectopic
mineralization was the sternocostal region. This distinct anatomical pattern of mineral
deposition in ENT1-/- mice suggests some common element in spinal and sternal
fibrocartilaginous tissues makes them susceptible to ectopic mineralization in the absence
of ENT1. Relatively scant vascular perfusion of the affected fibrocartilaginous tissues
could lessen the clearance of extracellular adenosine, giving rise to sustained adenosine
signaling which may in turn lead to deregulation of PPi metabolism.
The spatial and temporal pattern of ectopic mineralization observed in the ENT1-/mice, along with the absence of inflammation in affected tissues, resemble characteristics
of diffuse idiopathic skeletal hyperostosis (DISH) in humans. DISH affects about 20% of
the male population over the age of 55, with a slightly lower prevalence in women (35).
Similarly, in ENT1-/- mice, lesions developed gradually over time with functional
impairments noticeable by 8 months of age. Similar to DISH in humans, which is often
first diagnosed in the cervical or thoracic spine (64), lesions in ENT1-/- mice began in the
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cervicothoracic spine and spread caudally. Moreover, sternal involvement is also noted in
DISH patients (65). On the other hand, extra-axial calcifications are present in some
DISH patients, but were not detected by µCT or histology in ENT1-/- mice. Interestingly,
the reproducible pattern of mineral deposition observed in ENT1-/- mice was not related to
differences in endogenous ENT1 expression levels in the affected tissues. The factors
contributing to the timing of mineral deposition at these sites remains an intriguing
question for ongoing investigation. The radiographic appearance of DISH in humans
bears striking resemblance to that of ectopic mineralization in ENT1-/- mice. DISH is
characterized by tortuous paravertebral calcifications generally anterior to the vertebral
bodies (66). On gross examination the appearance is likened to that of candle wax
dripping down the spine. This appearance is remarkably similar to that observed in the
present study by µCT analysis of ENT1-/- mice.
In summary, this is the first report of a role for the primary membrane transporter
for adenosine, ENT1, in regulating the calcification of soft tissues in mice. Disruption of
purine homeostasis by removal of ENT1 leads to the ectopic mineralization of paraspinal
ligaments and intervertebral discs in mice, resembling lesions seen in the human
condition, DISH. Pathogenesis appears to be associated with both local and systemic
changes in PPi homeostasis. The ENT1-/- mouse may prove useful as a model for
investigating the mechanisms underlying ectopic mineralization associated with DISH
and for the evaluation of therapies for the prevention and reversal of DISH and associated
pathologies.
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Chapter 3

Disruption of Biomineralization Pathways in Spinal Tissues of
Mice Lacking Equilibrative Nucleoside Transporter 1 (ENT1)
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3.1 Chapter Summary
Recent studies have suggested a role for adenosine metabolism in the regulation
of biomineralization. Equilibrative nucleoside transporter 1 (ENT1) is a membrane
protein involved in the bi-directional transport of adenosine across the plasma membrane.
In mice lacking ENT1 (ENT1-/-), we reported the development of ectopic mineralization
of paraspinal tissues in the cervical-thoracic region at 2 months of age, which extended to
the lumbar and caudal regions with advancing age. Histological examination revealed
large, irregular accumulations of eosinophilic material in spinal fibrocartilaginous tissues
including ligaments, entheses and intervertebral discs. Plasma adenosine levels were
greater in ENT1-/- mice than in wild-type controls and elevated plasma levels of inorganic
pyrophosphate (PPi) in ENT1-/- mice indicated generalized disruption of pyrophosphate
homeostasis. This skeletal phenotype closely resembles a human disorder known as
diffuse idiopathic skeletal hyperostosis (DISH). DISH is a relatively common noninflammatory spondyloarthropathy, characterized by ectopic calcification of spinal
tissues. Its etiology is unknown and there are no specific treatments. The objectives of the
present study were i) to characterize expression of adenosine transporters and receptors in
spinal tissues; and ii) to investigate whether loss of ENT1 alters the expression of genes
that regulate biomineralization, and/or genes involved in adenosine metabolism and
signaling. Using quantitative RT-PCR, we compared gene expression in intervertebral
disc tissues obtained from 6-month-old male ENT1-/- and wild-type mice. No differences
were observed in genes encoding nucleoside transporters, adenosine receptors or
enzymes involved in adenosine metabolism. In contrast, intervertebral discs from ENT1-/mice exhibited reduced expression of genes involved in suppressing biomineralization,
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including: matrix gla protein (Mgp – an inhibitor of soft tissue mineralization);
ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1 – responsible for the
production of PPi, which inhibits mineralization); progressive ankylosis protein (Ank – a
putative PPi transporter); and osteopontin (Spp1 – an inhibitor of mineralization).
Unexpectedly, expression of alkaline phosphatase (Alpl – responsible for the hydrolysis
of PPi to Pi) was also reduced in ENT1-/- discs. Of note, no differences were observed in
the expression of these genes in tissues, including knee and liver, which do not exhibit
ectopic mineralization in ENT1-/- mice. These findings suggest that alterations in
regulatory proteins that normally prevent soft tissue mineralization contribute to the
ectopic calcification of spinal tissues in ENT1-/- mice. ENT1-/- mice may be a useful
model to investigate the etiology of and therapies for DISH and related disorders of
mineralization in humans.

3.2 Introduction
Aberrant calcification of soft connective tissues has been associated with a
number of skeletal disorders, such as diffuse idiopathic skeletal hyperostosis (DISH) (1).
DISH is a common non-inflammatory condition of the spine (2). It involves the
pathological calcification of the anterolateral spinal ligaments, entheses, and
fibrocartilaginous tissues present in the intervertebral discs (1,3,4). DISH often presents
as back pain and stiffness and is associated with increased vertebral fractures in the
elderly (5) and in severe cases, dysphagia (6) and compression of the spinal cord and
nerve roots (6-8). DISH is typically diagnosed by radiographic examination (9), and is
associated with the detection of distinct calcified outgrowths along the vertebrae of the
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thoracic spine or chest (2). The specific radiographic diagnostic criteria for DISH are 1)
flowing calcifications along anterolateral aspect of at least four continuous vertebral
bodies; 2) preservation of disc height in involved areas; and 3) absence of bony ankylosis
of facet joints and absence of sacroiliac erosion, sclerosis or fusion (10). There have been
no reported single gene defects associated with DISH, although single nucleotide
polymorphisms in the COL6A1 and FGF2 genes have been shown to confer genetic
susceptibility to DISH (11,12). Furthermore, several metabolic disorders are associated
with DISH including obesity, hypertension, diabetes mellitus, dyslipidemia, and
hyperuricemia (13-15).
Recent studies have begun to investigate the role of purinergic signaling,
specifically that of adenosine, in the physiology and pathophysiology of mineralized
tissues (16). Through characterization of mice lacking ecto-5’-nucleotidase (Nt5e),
Takedachi

and

colleagues

demonstrated

that

adenosine

promotes

osteoblast

differentiation via A2b adenosine receptor signaling (17). The Nt5e gene encodes the
CD73 cell-surface enzyme, which converts adenosine monophosphate (AMP) to
adenosine. It was found that CD73-/- mice had significantly lower bone mineral content
than wild-type controls; these mice also showed a significant decrease in serum levels of
osteocalcin, a metabolic marker of in vivo bone formation (17). Furthermore, real-time
PCR demonstrated a decreased expression of osteoblast markers in CD73-/- mice (17).
Building on these studies, St. Hilarie et al. demonstrated that mutations in NT5E resulting
in a non-functional CD73 enzyme show genetic associations with symptomatic arterial
and joint calcifications in humans (18). In addition, cultured fibroblasts from affected
individuals showed reduced expression of NT5E mRNA and the CD73 protein, increased
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tissue-nonspecific alkaline phosphatase (ALPL) enzyme activity, and the accumulation of
calcium phosphate crystals (18).

ALPL is an enzyme responsible for hydrolyzing

inorganic pyrophosphate (PPi – an inhibitor of mineralization) to phosphate (Pi – which
promotes calcification). These studies suggest a possible link between adenosine
metabolism and ectopic mineralization.
Recently, in mice lacking ENT1 (ENT1-/- mice), we reported the development of
ectopic mineralization in paraspinal tissues that resemble DISH (19). These mineralized
lesions originate at the cervical-thoracic region as early as 2 months of age, and extend to
the lumbar and caudal regions with advancing age (19). Histological examination
revealed

large,

irregular

accumulations

of

eosinophilic

material

in

spinal

fibrocartilaginous tissues including ligaments, entheses and intervertebral discs.
Interestingly, plasma adenosine levels were found to be significantly greater in ENT1-/mice than in wild-type controls (19).
ENT1 (equilibrative nucleoside transporter 1 or solute carrier family 29 member
1, encoded by the Slc29a1 locus) is a membrane protein involved in the bi-directional
transport of nucleosides across the plasma membrane (20). The ENT1-/- mouse was
originally created by Dr. Choi and colleagues to study the role of adenosine transport in
central nervous system pathways regulating alcohol consumption (21). Initial studies
demonstrated that at 3 months of age, ENT1-/- mice had <10% lower body weight, but
showed no differences in open-field locomotor activity, and had no evidence of gross
anatomical abnormalities in the brain compared to their wild-type littermate controls (21).
Studies have reported that the ENT1-/- mice consumed twice as much alcohol and
demonstrated a decreased ataxic effect of ethanol (21). These mice were also shown to
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exhibit reduced anxiety-like behaviors (22). Microvascular endothelial cells isolated from
ENT1-/- mice have enhanced expression of the A2A adenosine receptor and adenosine
deaminase (23). Cardiomyocytes from ENT1-/- mice appear to be protected from ischemic
insult and ENT1-/- mice show decreased myocardial infarction in response to ischemia
and hypoxia (24).
The present study was conducted to understand the molecular framework
underlying the development of ectopic mineralization in spinal tissues of the ENT1-/mouse. We specifically interrogated gene expression differences in affected tissues
isolated from ENT1-/- mice compared to their age- and gender-matched littermate wildtype controls to delineate the pathways through which disruption of adenosine signaling
contribute to the development of soft connective tissue mineralization.

3.3 Materials and Methods
3.3.1 Animals
ENT1-/- mice were generated through targeted deletion of exons 2 to 4 of the gene
encoding ENT1 by a cre-loxP targeting strategy (21). ENT1-/- mice were backcrossed
with C57BL/6 mice. The mouse colony was maintained through the breeding of
heterozygous animals (ENT1+/-) to obtain wild-type (ENT1+/+) and knockout (ENT1-/-)
littermates. Mice were housed in standard cages and maintained on a 12-hour light/dark
cycle, with rodent chow and water available ad libitum. Genotyping was performed as
described (23). Given the increased reported prevalence of DISH in males (25% of men
versus 15% of women over 50 years of age) (25), male mice were used for all
experiments. Mice were euthanized at 6 months (26-30 weeks). All aspects of this study
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were conducted in accordance with the policies and guidelines set forth by the Canadian
Council on Animal Care and were approved by the Animal Use Subcommittee of the
University of Western Ontario, London, ON.

3.3.2 Isolation of Intervertebral Discs and RNA Extraction
At 6 months of age, littermate-paired wild-type and ENT1-/- mice (n=8 for each
genotype) were dissected to isolate intact intervertebral discs (IVDs) inclusive of annulus
fibrosus, nucleus pulposus and cartilage endplates. IVDs from each animal were
separated according to anatomical location as cervical-thoracic, lumbar, or tail. Nonaffected tissues (including knee, heart, kidney, skeletal muscle, brain and liver) were also
harvested from wild-type animals (n=3). Tissues were placed directly in 1 mL of TRIzol
Reagent (Life Technologies, Wilmington, DE) and homogenized using a PRO250
Polytron benchtop homogenizer (PRO Scientific, Oxford, CT). Total RNA was extracted
according to the manufacturer’s protocol and quantified using a NanoDrop 2000
spectrophotometer (Thermo Scientific, Mississauga, ON). For each sample, 1 µg RNA
was reverse transcribed into cDNA using Superscript II Reverse Transcriptase (Life
Technologies).

3.3.3 Primer Design and Optimization
For SYBR-based RT-PCR, primers were designed using PrimerBank and
Integrated DNA Technologies with sequences specific to the gene of interest, to produce
an amplicon between 75 to 175 bp in length. Whenever possible, primers were designed
to flank an intron/exon boundary in order to detect gDNA contamination of RNA
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samples. For primer optimization, the primers were assessed using serial dilutions (5fold) of cDNA synthesized from a mix of wild-type heart, brain, kidney, muscle,
intervertebral disc, and calvarial RNA at a range of temperatures between 56-62oC to
optimize annealing/elongation temperatures. Standard curves were generated to control
for primer efficiency (70-120%) and specificity of primers were determined by melt
curve analysis (0.5C/5 s).

3.3.4 Quantitative real-time RT-PCR
Gene expression patterns were determined by real-time PCR using the Bio-Rad
CFX384 system. PCR reactions were run in triplicate, using 25 µM forward and reverse
primers (primer sequences provided in Table 3.1) with 2X SsoFast EvaGreen Supermix
(Bio-Rad, Mississauga, ON). The PCR program consisted of the following: initial 3 min
at 95oC for denaturing; 95oC for 10 s denaturing; 30 s annealing/elongation (temperatures
provided in Table 3.1), for a total of 40 cycles. Gene transcript levels were determined
relative to a six-point calibration curve made from cDNA generated from heart, brain,
kidney, muscle, intervertebral disc, and calvarial RNA (isolated from wild-type mice).
The starting concentration of the cDNA standard (83 – 136 ng/µl) was inputted into the
Bio-Rad CFX Manager 2.0 software to generate the standard curve (1/5 serial dilution).
Values for gene transcript levels are expressed relative to the calibration curve in ng/µl.
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Table 3.1: Real-time PCR Primer Sequences
Gene
Name
Ada
Adk
Adora1
Adora2a
Adora2b
Adora3
Ank
Alpl
Bglap
Col10a1
Enpp1
ENT1
ENT2
ENT3
ENT4
Gdf10
Ibsp
Mgp
Nt5e
Pnp
Runx2
Spp1
Xdh

Primer Sequence (5’ to 3’)

Annealing/Elongation
Temperature (oC)

Fwd – ACAATCAGAAGACCGTGGTGGCTA
Rev – TCTTTACTGCGCCCTCATAGGCTT
Fwd – CTCAGTGGTTGATTCAGGAGC
Rev – CAGCCTTACGCTTCAGGATCT
Fwd – ATCCCTCTCCGGTACAAGACAGT
Rev – ACTCAGGTTGTTCCAGCCAAAC
Fwd – CCGAATTCCACTCCGGTACA
Rev – CAGTTGTTCCAGCCCAGCAT
Fwd – ATGCAGCTAGAGACGCAAGAC
Rev – GGGATACCAGAAAGTAGTTGGTG
Fwd – ACTTCTATGCCTGCCTTTTCATGT
Rev – AACCGTTCTATATCTGACTGTCAGCTT
Fwd – CCCTGATAGCCTACAGTGACTTAGG
Rev – GAAGGCAGCGAGATACAGGAA
Fwd – CCAACTCTTTTGTGCCAGAGAA
Rev – GGCTACATTGGTGTTGAGCTTTT
Fwd – CTGACCTCACAGATCCCAAGC
Rev – TGGTCTGATAGCTCGTCACAAG
Fwd – GGGACCCCAAGGACCTAAAG
Rev – GCCCAACTAGACCTATCTCACCT
Fwd – CAAAACCCACAATGACTGTTGC
Rev – CTGGACACTCCGGGGTATCG
Fwd – CAAGTATTTCACAAACCGCCTGGAC
Rev – GAAACGAGTTGAGGCAGGTGAAGAC
Fwd – TCATTACCGCCATCCCGTACT
Rev – CCCAGTTGTTGAAGTTGAAAGTG
Fwd – AGCCTCACTCTTTCCAGCTGACAT
Rev – ACTTGGTGTCTGTGTCGTTCCTGT
Fwd – TGCTGTCCATTGCGGTAACCTACT
Rev – TTGCCCACAAAGTCTGACAGGTTG
Fwd – GAAGTACAACCGAAGAGGTGC
Rev – AGGCTTTTGGTCGATCATTTCC
Fwd – ACGGCGATAGTTCCGAAGAG
Rev – CTAGCTGTTACACCCGAGAGT
Fwd – GGCAACCCTGTGCTACGAAT
Rev – CCTGGACTCTCTTTTGGGCTTTA
Fwd - GGAGCTCACGATCCTGCACACAAA
Rev – TCCCAGTGCCATAGCATCGTAGCC
Fwd - GCCGACTGGTGTTTGGATTGCTG
Rev – TCGTTGCTCCCCCATTTGTTTCC
Fwd - ATGGCTTGGGTTTCAGGTTAGGGA
Rev – TGGAGTGAAGGATGAGGGCAAACT
Fwd - AAGCAAGAAACTCTTCCAAGCAA
Rev – GTGAGATTCGTCAGATTCATCCG
Fwd – ATGACCGCCTTCAGAACAAGA
Rev – TGTCACAGCAACATGATGCAA
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60
60
56
56
60
56
56
60
60
60
56
56
56
60
56
60
60
56
56
56
60
56
60

3.3.5 Statistical Analyses
Differences in gene expression levels between IVD tissues from distinct
anatomical spine regions (cervical-thoracic, lumbar, and tail) and non-affected tissues
(knee, heart, kidney, muscle, brain, and liver) within wild-type animals were compared
using a one-way ANOVA with Bonferroni’s post-hoc test in GraphPad Prism 5
(GraphPad Software, Inc., La Jolla, CA). For comparison of gene expression levels
between wild-type and ENT1-/- animals in IVD tissues isolated from specific anatomical
regions, Student’s t-test analysis was conducted using GraphPad Prism 5. For all analysis,
significance was indicated as p < 0.05.

3.4 Results
Our previous studies established that hypermineralization of the ENT1-/- mouse
was restricted to paraspinal fibrocartilaginous tissues and sternocostal articulations. In
contrast, examination of appendicular joints revealed no aberrant morphology or
evidence of ectopic mineralization, establishing that lesions are specifically associated
with the axial skeleton. Furthermore, within the spine, there was a reproducible pattern of
mineralization that progressed from cervical to caudal with age (19). We wanted to
interrogate whether the temporal and spatial pattern of these hypermineralized lesions
was due to differences in the levels of endogenous equilibrative nucleoside transporter
and adenosine receptor expressions.
Quantitative real-time PCR was performed to characterize the endogenous gene
expression of equilibrative nucleoside transporters and adenosine receptors in distinct
tissues of wild-type mice. The gene expression levels in IVDs from distinct anatomical

98

regions (cervical-thoracic, lumbar and tail) were compared to tissues not affected by
hypermineralization in the ENT1-/- mouse, which include the knee, heart, kidney, muscle,
brain and liver. The knee sample included the entire joint, which encompassed
fibrocartilaginous tissues of the meniscus and tendons, as well as articular cartilage and
subchondral bone. The gene expression levels of ENT1 were found to be comparable
between IVD tissues and other tissues examined (Fig 3.1A). In contrast, the expression of
related transporters ENT2, ENT3, and ENT4 was significantly lower in the IVD and knee
tissues compared to tissues of the heart, kidney and brain in which previous studies have
reported robust ENT expression (26,27) (Fig. 3.1B-D). Plasma adenosine levels were
found to be significantly greater in ENT1-/- mice than in wild-type controls, and therefore
it was logical to investigate whether the expression of adenosine receptors was altered in
response to elevated adenosine levels. The gene expression levels of Adora1, Adora2b,
and Adora3 in IVD tissues was significantly lower compared to tissues of the heart,
kidney, and brain (Fig 3.2 A, C-D). However, the gene expression level of Adora2a in
IVD tissues was significantly lower only when compared to tissues of the brain (Fig. 3.2
B).
Having established the endogenous distribution of adenosine transporters and
receptors in IVD tissues in comparison to other tissue types, real-time PCR was then used
to investigate whether loss of ENT1 alters the expression of genes associated with
adenosine metabolism and signaling, or extracellular matrix mineralization in
intervertebral disc tissues. For this analysis, IVD tissues were isolated from male ENT1-/and wild-type littermate control mice at 6 months of age based on anatomical location.
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Figure 3.1: Gene expression analysis of equilibrative nucleoside transporters in
tissues isolated from 6-month-old wild-type mice.
Real-time PCR analysis shows the gene expression of (A) ENT1, (B) ENT2, (C) ENT3, and
(D) ENT4 in wild-type animals in intervertebral discs (IVD) isolated from the cervicalthoracic (CT), lumbar or tail regions, knee, heart, kidney, muscle, brain and liver. Data are
presented as the mean ± SEM, n = 8 animals for IVD, and n = 3 animals for other tissues.
Values for gene transcript levels are expressed relative to a calibration curve in ng/µl as
described in the materials and methods. Bars labeled with the same letter are not significantly
different, based on one-way ANOVA with Bonferroni’s post-hoc test.
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D

Figure 3.2: Gene expression analysis of adenosine receptors in tissues isolated from
6-month-old wild-type mice.
Real-time PCR analysis shows the gene expression of (A) Adora1, (B) Adora2a, (C)
Adora2b, and (D) Adora3 for wild-type animals in intervertebral discs (IVD) isolated
from the cervical-thoracic (CT), lumbar or tail regions, knee, heart, kidney, muscle, brain
and liver. Data are presented as the mean ± SEM, n = 8 animals for IVD, n = 3 animals
for other tissues. Bars labeled with the same lower case letter are not significantly
different, based on one-way ANOVA with Bonferroni’s post-hoc test
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Gene expression values for each transcript in heart tissue (isolated from wild-type mice)
are presented as a positive control to compare relative abundance. We first interrogated
the expression of genes encoding the ENT transporters to determine if there was a
compensatory effect due to the loss of ENT1. No significant differences were observed
in the expression of ENT2, ENT3, or ENT4 between ENT1-/- and wild-type mice within
each anatomical region (Fig. 3.3). Similarly, there were no differences observed in the
expression of adenosine receptors in ENT1-/- mice compared to wild-type mice within
each anatomical region (Fig. 3.4).
Since ENT1 is the predominant nucleoside transporter expressed in mammalian
cells, and plasma adenosine levels were found to be higher in ENT1-/- mice than wild-type
(19), we next investigated whether the expression of genes associated with the adenosine
metabolism pathway were altered in the knockout mice. Adenosine kinase (Adk) is an
enzyme that catalyzes the transfer of a phosphate from ATP to adenosine to form AMP;
adenosine deaminase (Ada) metabolizes adenosine to inosine (another nucleoside); purine
nucleoside phosphorylase (Pnp) is involved in the conversion of a nucleoside to a
nucleobase, such as inosine to hypoxanthine; xanthine dehydrogenase (Xdh) catalyzes
hypoxanthine to xanthine, and eventually to uric acid; and ecto-5'-nucleotidase (Nt5e)
generates adenosine from the breakdown of AMP. No significant differences were
observed in the expression of these adenosine metabolism enzymes in IVD tissues of
ENT1-/- mice compared to wild-type mice within each anatomical region (Fig. 3.5).
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Figure 3.3: Gene expression analysis of equilibrative nucleoside transporters in
intervertebral discs isolated from 6-month-old wild-type mice and ENT1-/- mice.
Real-time PCR analysis revealed no significant differences in the expression of (A)
ENT2, (B) ENT3 or (C) ENT4 between wild-type and ENT1-/- mice in specific spinal
regions. Gene expression values for heart tissue isolated from wild-type mice only are
presented as a positive control to compare relative abundance. Data are presented as the
mean ± SEM, n = 8 animals. Black bar = WT and white bar = ENT1-/- mice.
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Figure 3.4: Gene expression analysis of adenosine receptors in intervertebral discs
isolated from 6-month-old wild-type mice and ENT1-/- mice.
Real-time PCR analysis revealed no significant differences in the gene expression of (A)
Adora1, (B) Adora2a, (C) Adora2b or (D) Adora3 between wild-type and ENT1-/- mice in
specific spinal regions. Gene expression values for heart tissue isolated from wild-type
mice only are presented as a positive control to compare relative abundance. Data are
presented as the mean ± SEM, n = 8 animals. Black bar = WT and white bar = ENT1-/mice.
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Figure 3.5: Gene expression analysis of adenosine metabolism genes in
intervertebral discs isolated from 6-month-old wild-type mice and ENT1-/- mice.
Real-time PCR analysis revealed no significant differences in the expression of (A) Adk,
(B) Ada, (C) Pnp, (D) Xdh or (E) Nt5e between wild-type and ENT1-/- mice in specific
spinal regions. Data are presented as the mean ± SEM, n = 8 animals. Black bar = WT
and white bar = ENT1-/- mice. α = significantly different between wild-type (p < 0.05,
one-way ANOVA with Bonferroni’s post-hoc test).
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Given that ENT1-/- mice demonstrate progressive mineralization of paraspinal
fibrocartilaginous tissues (19), we interrogated the expression of genes associated with
extracellular matrix mineralization in IVD tissues. Compared to wild-type mice, we
observed reduced expression of genes involved in suppressing biomineralization in
ENT1-/- mice, including matrix gla protein (Mgp – an inhibitor of soft tissue
mineralization, Fig. 3.6A); ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1 –
responsible for the production of pyrophosphate, PPi, which inhibits mineralization, Fig.
3.6B); progressive ankylosis protein (Ank – a putative PPi transporter, Fig. 3.6C); and
osteopontin (Spp1 – another inhibitor of mineralization, Fig. 3.6D). All four genes
showed significantly reduced expression in ENT1-/- mice compared to wild-type in IVDs
isolated from the cervical-thoracic region, the anatomical region most severely affected
by ectopic mineralization at the 6 month time point; Enpp1 also showed reduced
expression in IVDs of the lumbar region of ENT1-/- mice compared to wild-type gene
expression levels (Fig. 3.6B). Importantly, no differences were observed in the expression
of these genes between wild-type and ENT1-/- mice in tissues of the knee or liver, which
do not exhibit ectopic mineralization (Fig. 3.6).
Unexpectedly, expression of tissue nonspecific alkaline phosphatase (Alpl) was
found to be significantly decreased in IVDs of the cervical-thoracic and lumbar regions
of ENT1-/- mice compared to wild-type (Fig. 3.7). Tissue-nonspecific alkaline
phosphatase is responsible for the hydrolysis PPi to Pi, which promotes mineralization
(28). No differences were observed in the expression of Alpl between wild-type and
ENT1-/- mice in tissues of the knee or liver (Fig. 3.7).
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Figure 3.6: Gene expression analysis of mineralization associated genes in
intervertebral discs (IVD), knee, and liver isolated from 6-month-old wild-type mice
and ENT1-/- mice.
Real-time PCR analysis of genes associated with tissue mineralization revealed
significant reductions in the expression of (A) Mgp in the cervical-thoracic region, (B)
Enpp1 in the cervical-thoracic and lumbar regions, (C) Ank in the cervical-thoracic
region, and (D) Spp1 in the cervical thoracic region in ENT1-/- mice compared to wildtype controls. There were no significant differences in gene expression in the knee or
liver of the ENT1-/- mice compared to wild-type controls. Data are presented as the mean
± SEM, n = 8 animals. Black bar = WT and white bar = ENT1-/- mice. * Significantly
different from same tissue isolated from wild-type (p < 0.05, Student’s t-test).
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Figure 3.7: Gene expression analysis of alkaline phosphatase in intervertebral discs
(IVD) isolated from 6-month-old wild-type mice and ENT1-/- mice.
Real-time PCR analysis revealed a significant reduction in the expression of Alpl for
cervical-thoracic and lumbar regions in ENT1-/- mice compared to wild-type controls.
There were no significant differences in gene expression in the knee or liver in ENT1-/mice compared to wild-type controls. Data are presented as the mean ± SEM, n = 8
animals. Black bar = WT and white bar = ENT1-/- mice. * Significantly different from
same tissue isolated from wild-type (p < 0.05, Student’s t-test).
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Our previous studies demonstrated that within fibrocartilaginous tissues, areas of
ectopic calcification were surrounded by a clearly defined transition zone (19). Adjacent
to fibrocartilaginous tissue with a typical histological appearance, this transition zone was
characterized by metaplasia, with cells displaying eosinophilic nuclei that stained
positively with DAPI, revealing an intact nuclear structure. To determine if cells within
this tissue were undergoing a change in cell phenotype, we assessed the expression of
markers associated with annulus fibrosus cells of the IVD (integrin binding sialoprotein,
Ibsp, and growth differentiation factor 10, Gdf10), hypertrophic chondrocytes (runt
related transcription factor 2, Runx2, and collagen, type X, alpha 1, Col10a1) and bone
(Runx2 and osteocalcin, Bglap) lineage. Real-time PCR analysis revealed no differences
in the expression of Ibsp (Fig 3.8A) but a significant reduction in the expression of Gdf10
(Fig. 3.8B) in IVDs from the cervical-thoracic of ENT1-/- mice compared to wild-type. No
significant differences were detected in the expression of Runx2 or Col10a1 between
wild-type and ENT1-/- mice (Fig. 3.8C,D). In contrast, expression of Bglap was
significantly reduced in IVDs from the cervical-thoracic region of the ENT1-/- mice
compared to wild-type (Fig. 3.8E).

3.5 Discussion
The first report of a role for the nucleoside transporter ENT1 in regulating
biomineralization was the recent description by our group of ectopic mineralization in
fibrous connective tissues of the spine and sternum of ENT1-/- mice (19). In these studies,
ENT1-/- mice were characterized at various ages (from 1 to 17 months of age) using a
combination of histology and µCT imaging. Aberrant mineralization was first detected
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Figure 3.8: Gene expression analysis of markers associated with phenotypic
transition in intervertebral discs isolated from 6-month-old wild-type mice and
ENT1-/- mice.
Real-time PCR analysis examining the expression of markers associated with the annulus
fibrosus (A, B), hypertrophic chondrocyte (C, D) and osteoblast (C, E) phenotype.
Quantification revealed significant reductions in the expression of (B) Gdf10 and (E)
Bglap in the cervical-thoracic region of ENT1-/- mice compared to wild-type controls.
There were no significant changes in the expression of (A) Ibsp, (C) Runx2, (D) or
Col10a1 in ENT1-/- mice compared to wild-type controls. Data are presented as the mean
± SEM, n = 8 animals. Black bar = WT and white bar = ENT1-/- mice. * Significantly
different from same tissue isolated from wild-type (p < 0.05, Student’s t-test).
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between 6-8 weeks of age in the paraspinal connectives tissues of the cervical vertebrae;
lesions were found to increase in severity and affected the thoracic, lumbar, caudal spine
and sternocostal articulations with advancing age. Atypical mineralization was initially
observed in paraspinal fibrocartilaginous tissues including paraspinal ligaments and
entheses, and later detected in the annulus fibrosus of intervertebral discs and sternocostal
articulations.
Despite a systemic loss of ENT1 function, our previous studies establish that
ectopic mineralization in ENT1-/- mice is limited to fibrocartilaginous paraspinal tissues
and sternocostal articulations. While previous studies have characterized the relative
expression of murine ENT genes in various tissue types (26,27), musculoskeletal tissues
including the IVD were not included in these analyses. The present study shows that in
wild-type mice, ENT1 mRNA levels within the IVD are similar to levels expressed in
other tissue types such as the heart, kidney, muscle, brain and liver, while the mRNA
levels of ENT2, ENT3 and ENT4 levels within the IVD are lower than tissues of the heart,
kidney, and brain. Interestingly, tissues of the knee which do not demonstrate aberrant
mineralization in ENT1-/- mice (19), appeared to have lower levels of ENT1 gene
expression than levels expressed in IVD tissues. The tissue-specific expression pattern of
mouse ENT1 reported in the current study is consistent with previous reports, where
ENT1 mRNA in male mice was found to be higher in the liver and similar in the heart,
kidney, muscle and brain (26). The tissue distribution of ENT2 and ENT3 levels is also
similar to the previous study (26).
We further established an absence of compensatory upregulation of ENT2, ENT3,
or ENT4 gene expression in IVD tissues of the ENT1-/- mice. This is consistent with
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previous studies that demonstrated gene expression levels of ENT2, ENT3, and ENT4
were similar in cardiomyocytes isolated from ENT1-/- mice compared with those isolated
from wild-type littermates (24). Although a small but significant increase was reported in
ENT3 transcript levels in microvascular endothelial cells of ENT1-/- mice compared to
wild-type cells, no increase in ENT3 protein levels was detected (23). Taken together,
these findings suggest that in tissues from ENT1-/- mice, there appears to be no
compensation by ENT2, ENT3, or ENT4 gene expression, with the lack of ENT1.
Compared to other tissues which demonstrate detectable expression of multiple ENTs, we
have shown the relative abundance of equilibrative nucleoside transporter levels in the
IVDs, which demonstrate that the IVDs rely predominantly on ENT1. ENT1 has been
established as a predominant nucleoside transporter in mammalian cells and
consequently, it is then possible that with the absence of ENT1, the knockout mice
develop an aberrant mineralized skeletal phenotype.
Our previous studies demonstrated that plasma adenosine levels were
significantly elevated in ENT1-/- mice. Given the potential impact of disrupted adenosine
signaling, we first investigated the endogenous expression of adenosine receptor
expression in IVD tissues. The gene expression levels of Adora1, Adora2b, and Adora3
in IVD tissues was significantly lower compared to tissues such as the heart, kidney, and
brain. However, the gene expression level of Adora2a in IVD tissues was significantly
lower only when compared to tissues of the brain. Our findings are consistent with
previous studies that reported expression of Adora1 throughout the central nervous
system (CNS), heart, kidney and liver (29) and Adora2a expression in the CNS (29) and
heart (30). Previous studies suggest a more widespread expression of Adora2b; whereas
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Adora3 expression has been reported to be enriched in brain tissues and liver, detected in
the heart and kidney, and not detected in skeletal muscle (29). Compared to tissues of the
heart, kidney, and brain, we have observed low gene expressions of adenosine receptors
in the IVDs, which suggests that the presence of adenosine receptors may not play a big
role in the development of the skeletal phenotype observed in the ENT1-/- mice.
Although we have shown that there are elevated plasma adenosine levels in the
ENT1-/- mice, we have yet to investigate the levels of adenosine within the spinal tissue.
Similar to our findings for ENT gene expression, no significant differences in the
expression of adenosine receptors were detected in ENT1-/- mice compared to wild-type
mice. A lack of change in the mRNA levels of adenosine receptors suggests that protein
levels of adenosine receptors may not change. However, it is likely that adenosine
receptor signaling is different in ENT1-/- mice because of differences in the extracellular
concentration of adenosine, or changes in intracellular signal coupling. Previous reports
suggest that changes in adenosine receptor expression in ENT1-/- mice may be cell-type
dependent. In cardiomyocytes isolated from ENT1-/- mice, no significant differences were
reported in the expression of adenosine receptor subtypes (24), whereas enhanced
expression of Adora2a was reported in microvascular endothelial cells isolated from
ENT1-/- mice (23). Furthermore, suggesting that loss of ENT1 does not alter adenosine
metabolism in IVD tissues, we demonstrate no significant differences in the expression of
adenosine metabolism enzymes (Adk, Ada, Pnp, Xdh, Nt5e) in ENT1-/- mice compared to
wild-type control. Gene expression studies suggest that at 6 months of age, adenosine
signaling and metabolism pathways do not appear to be altered in IVD tissues of ENT1-/mice, but further studies are required to assess levels of adenosine within our tissue of
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interest and measure active signaling.
Previous studies have demonstrated that purine metabolism and signaling play a
critical role in the regulation of biomineralization and diseases associated with aberrant
mineralization (9,16,18,31-33). In the current study, we report a significant decrease in
Mgp expression in IVD tissues of ENT1-/- mice isolated from anatomical regions that
demonstrate ectopic mineralization at 6 months. MGP is an extracellular matrix
glycoprotein that contains γ-carboxyl groups, which allow it to chelate calcium and
function as an inhibitor of tissue mineralization (34). MGP deficiency in mice results in
premature calcification, aberrant mineralization of growth plate cartilage, leading to short
stature, osteopenia and fractures, and severe arterial calcification leading to premature
death (35). The corresponding human disorder is known as Keutal syndrome,
characterized by abnormal cartilage calcification, peripheral pulmonary stenosis and
midfacial hypoplasia (36). In addition, the tiptoe walking mouse (ttw, a spontaneous
recessive mutant), shows disruption of the annulus fibrosus arrangement in IVDs and has
been suggested to be associated with the abnormal expression of MGP (37). Interestingly,
SPP1 is also a putative inhibitor of mineralization (38,39) and we demonstrate that its
expression is downregulated in IVD tissues of ENT1-/- mice in regions associated with
ectopic mineralization at 6 months. Decreased expressions of these inhibitors of tissue
mineralization contribute to the ectopic mineralization observed in the ENT1-/- mice.
When ATP is released by the cell, it is sequentially metabolized by cell-surface
enzymes to produce adenosine. ENPP1 is responsible for the first step in this process and
serves as a physiological regulator of calcification via the production of adenosine
monophosphate (AMP) and inorganic pyrophosphate (PPi), the latter of which inhibits
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ectopic calcification in soft tissues (40). Extracellular PPi is also regulated by ANK, a
transmembrane protein postulated to transport PPi across the plasma membrane to the
extracellular environment (41). We show a significant downregulation of Enpp1 and Ank
expression in IVD tissues of ENT1-/- mice in regions of associated ectopic mineralization
at 6 months of age. Enpp1-/- mice have been shown to exhibit soft tissue mineralization in
paraspinal ligaments, intervertebral discs, Achilles tendon and calcification of articular
cartilage, and peripheral joint hyperostosis (28). Mutations in Enpp1 have been also been
linked to mineralization disorders such as ossification of the posterior longitudinal
ligament (42) and generalized arterial calcification of infancy and hypophosphatemic
rickets (43). In mice, mutations in Ank lead to mineral deposition in the articular cartilage
and synovial fluid (41,44), and eventual generalized joint fusion (45,46). In humans,
dominant ANK mutations are associated with craniometaphyseal dysplasia (47,48) and
familial chondrocalcinosis (49,50). Therefore, we postulate that reduced expression of
Enpp1and Ank would lead to reduced extracellular PPi levels, and thus increased tissue
mineralization.
Interestingly, the changes in gene expression associated with the regulation of
mineralization were found to correlate with the temporal progression of mineralization
reported in ENT1-/- mice (19). At the 6 month time point examined in these studies,
mineralization was reported in >60% of the cervical and thoracic spine, 30% of the
lumbar spine, and was not detected in the caudal spine. The fact that significant changes
in Mgp, Enpp1, Ank, and Spp1 gene expression were restricted to IVDs of the cervicalthoracic spine of ENT1-/- mice suggests that observed changes are secondary to the
initiation of mineralization. Furthermore, no significant differences were observed in the
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expression of these genes in other tissues including the knee and liver, which do not
exhibit ectopic mineralization in ENT1-/- mice. We also observed that gene expression in
caudal IVDs is different from the gene expression in cervical-thoracic and lumbar IVDs
in wild-type mice. Real-time PCR analysis revealed a significantly higher expression of
ENT4 and Adora3 in the tail IVDs compared to the lumbar IVDs; expression of Xdh was
significantly lower in the tail IVDs compared to the cervical-thoracic IVDs; and Mgp
expression was significantly higher in tail IVDs compared to cervical-thoracic IVDs. It is
possible that these differences in gene expression contribute to the fact that the tail IVDs
are the last to demonstrate ectopic mineralization in the spine. Further studies are
required to explore the mechanism(s) underlying this phenomenon.
Unexpectedly, expression of Alpl was significantly reduced in IVDs of the
cervical-thoracic and lumbar spine of ENT1-/- mice compared to control tissue. ALPL
promotes mineralization by catalyzing the hydrolysis of PPi, thereby decreasing the local
concentration of this calcification inhibitor, while increasing the levels of Pi (28). Alpl-/mice mimic a severe form of hypophosphatasia, characterized by rickets, spontaneous
bone fractures, osteomalacia, and elevated PPi levels, and die before weaning (51). In
humans, disruption of ALPL causes hypophosphatasia, characterized by skeletal
hypomineralization (52). It is possible that the reduction of Alpl in the spinal tissues of
ENT1-/- mice at 6 months of age (at which age lesions are present in the cervical, thoracic
and lumbar regions) is a result of excessive mineral present in the extracellular matrix. As
a consequence, lower levels of Alpl would attempt to decrease further mineralization.
In our initial characterization of ENT1-/- mice, we noted that early foci of
mineralization in fibrocartilaginous structures were associated with a clearly defined
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transition zone that contained cells with eosinophilic nuclei and a hypertrophic
appearance (19). To begin to examine whether ectopic mineralization was associated with
a phenotypic conversion of the associated fibrocartilaginous cell types, we examined the
expression of cell-type specific markers. To investigate the disruption of the annulus
fibrosus phenotype, we quantified the expression of Ibsp and Gdf10. While levels of Ibsp
expression were unchanged, a significant reduction in the expression of Gdf10 was
detected in IVDs from the cervical-thoracic region of ENT1-/- mice compared to wildtype tissues, which may suggest alterations in the annulus fibrosus phenotype. No
differences were detected in the expression of either Runx2 or Col10a1 in IVD tissues
from ENT1-/- mice compared to wild-type, markers associated with the osteoblast (53)
and hypertrophic chondrocyte lineages (54,55). In contrast, expression of osteocalcin
(Bglap), an abundant non-collagenous bone matrix protein, which has been previously
reported to be specific to osteoblasts (56,57), was significantly reduced in IVDs of the
cervical-thoracic region of the ENT1-/- mice compared to wild-type tissues. There have
been contradictory results over the role of osteocalcin in bone mineralization. Ducy et al.
showed that osteocalcin-deficient mice had increased bone density without a change in
bone resorption or mineralization, suggesting that osteocalcin directly inhibits
osteoblastic bone formation (58). However, some studies show a positive correlation
between osteocalcin concentration and mineralization (59). Furthermore, the involvement
of osteocalcin in bone resorption has also been demonstrated, principally in the regulation
of osteoclast formation and activity (60,61). Despite controversial data, the dual role of
osteocalcin in bone can be presumed: firstly, osteocalcin regulates bone remodeling by
modulating osteoblasts and osteoclast activity, secondly, it acts as a regulator of bone
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mineralization (62). Taken together, these results suggest that the development of ectopic
lesions within the fibrocartilaginous tissue of the IVD in ENT1-/- mice is not associated
with the phenotypic conversion of annulus fibrosus cells to either a hypertrophic
chondrocyte or osteoblastic lineage. Further studies are required to understand the
specific cellular changes associated with the metaplasia and initiation of tissue
mineralization in ENT1-/- mice.
In summary, the present study was conducted to begin to elucidate the molecular
framework underlying the progressive mineralization of paraspinal tissues in the ENT1-/mouse. The pattern of ectopic mineralization observed in ENT1-/- mice is intriguing as
pathological changes are restricted to the spine and sternocostal regions, despite being a
whole-body knockout of ENT1 and demonstrates a reproducible temporal pattern of
development (19,21). The current data suggests that spinal tissues may be affected by
ectopic mineralization due to the endogenous expression of ENTs, which shows that
ENT1 is the predominant nucleoside transporter in IVDs. Furthermore, as demonstrated
by real-time PCR, there appears to be no compensation by related transporters for the loss
of ENT1. The data also shows significant changes in the expression of genes involved in
the suppression of biomineralization that may contribute to calcification. Since there is a
downregulation of mineralization associated genes, pathogenesis also appears to be
associated with changes in PPi homeostasis. In addition, although the annulus fibrosus is
affected in the IVD with lesions, changes do not appear to be correlated with the
phenotypic conversion of annulus fibrosus cells to either a hypertrophic chondrocyte or
osteoblast lineage. A limitation of this study was the targeted candidate gene approach
used to evaluate changes in gene expression; furthermore, these changes are yet to be
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verified by protein data. In order to investigate changes associated with the early
induction of tissue mineralization, we propose that identification of primary changes will
require a more global approach to analysis, including microarray or proteomic
quantification at an earlier time-point. Understanding the ENT1-/- mouse may be
advantageous for investigating the mechanisms of ectopic mineralization observed in
DISH and associated mineralization disorders.
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Chapter 4

General Discussion
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4.1 Summary and Conclusions
The studies presented in this thesis were undertaken based on a preliminary
observation that mice lacking the gene encoding ENT1 developed progressive ectopic
mineralization of spinal tissues. We hypothesized that: loss of ENT1 leads to
progressive accumulation of ectopic mineral in paraspinal tissues due to altered
expression of genes that regulate biomineralization.
We sought to explore this hypothesis with the following specific objectives:
1) Characterize pathological changes in paraspinal tissues in ENT1-/- mice over time
pertaining specifically to hypermineralization.
2) Determine changes in the expression of genes associated with adenosine transport
and metabolism, as well as, extracellular matrix mineralization in the ENT1-/mice compared to wild-type controls.

In chapter two, we characterized the temporal and spatial pattern of the
mineralized lesions present in the ENT1-/- mice.
Conclusion 2.1: Mice lacking functional ENT1 demonstrate ectopic mineralization
restricted to paraspinal, intervertebral and sternocostal fibrocartilaginous tissues. There
was no evidence of mineralization in appendicular joints or blood vessels, indicating
specificity of the axial skeleton.
Conclusion 2.2: ENT1-/- mice demonstrate a reproducible temporal pattern of
mineralization which originates in the cervical paraspinal ligaments at 2 months of age,
and extends towards the thoracic, lumbar, and caudal region with age involving
intervertebral disc (IVD) tissues and sternocostal joints.
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Conclusion 2.3: Micro-computed tomography (µCT) imaging of radio-opaque
mineralized lesions in the spinal tissues of ENT1-/- mice bear striking resemblance to the
radiographic appearance of spinal lesions characteristic of diffuse idiopathic skeletal
hyperostosis (DISH) in humans.

In chapter three, we investigated the molecular framework underlying the
development of ectopic mineralization of spinal tissues in the ENT1-/- mouse. We first
characterized the endogenous expression of nucleoside transporters and adenosine
receptors in spinal tissues, and then interrogated gene expression differences in affected
tissues isolated from ENT1-/- mice compared to their age- and gender-matched littermate
wild-type controls. Using a targeted candidate gene approach, these studies sought to
delineate the pathways through which disruption of adenosine signaling contribute to the
development of soft connective tissue mineralization.
Conclusion 3.1: In wild-type mice, the gene expression levels of ENT1 within the IVDs
are similar to levels expressed in other tissue types such as the heart, kidney, muscle,
brain and liver. In contrast, the gene expression levels of related transporters, ENT2,
ENT3, and ENT4 were significantly lower in the IVD and knee tissues compared to
tissues of the heart, kidney and brain.
Conclusion 3.2: Compared to wild-type, expression of genes encoding nucleoside
transporters, adenosine receptors, or enzymes involved in adenosine metabolism were not
altered in IVDs isolated from ENT1-/- mice.
Conclusion 3.3: Gene expression findings suggest that decreased gene expression of
regulatory proteins that normally prevent soft tissue mineralization (Mgp, Enpp1, Ank,
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Spp1) may contribute to the ectopic calcification of spinal tissues in ENT1-/- mice.
Furthermore, elevated plasma levels of inorganic PPi in ENT1-/- mice indicate generalized
disruption of pyrophosphate homeostasis.

4.2 Significance of Research
Is the ENT1-/- mouse a model for diffuse idiopathic skeletal hyperostosis (DISH)?
DISH is a common human disorder which involves the calcification of the
anterior longitudinal ligament, paraspinal connective tissues and annulus fibrosus (1,2).
DISH is often underdiagnosed and widely misdiagnosed (3); this is due to the fact that it
is primarily diagnosed though radiographs of the thoracic spine or chest, which are
usually taken due to another disease or injury (4). The etiology of DISH is unknown, and
currently there are no specific treatments. It has been proposed that lesions originate in
fibrous and fibrocartilaginous structures including entheses, however the underlying
pathogenesis remains obscure since prior to our studies, no suitable animal model had
been reported to pursue mechanistic studies.
In this study, we observed that the lesions of ectopic mineralization present at the
cervical and upper thoracic regions of ENT1-/- mice resemble the radiographic appearance
of lesions present in patients diagnosed with DISH. The ectopic calcification observed in
the ENT1-/- mice is restricted to paraspinal ligaments, entheses, intervertebral discs and
sternocostal regions. However, it is important to note that although the thoracic spine is
most commonly affected, appendicular joints such as metacarpophalangeal joints,
elbows, and shoulders are also affected in DISH (5-9). Entheseal ossification of the heel,
ribs, and pelvis are also common findings in DISH (5).
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Equilibrative nucleoside transporters (ENTs) are sodium-independent, facilitative
diffusion transporters which transport nucleosides bi-directionally down a concentration
gradient. ENTs are found distributed among various cell types (10,11) and consist of four
members (ENT1, ENT2, ENT3, ENT4) which share an ability to transport adenosine but
differ in their abilities to transport other nucleosides and molecules (12). Recent advances
point to a critical role for purine metabolism in the regulation of biomineralization in
diseases associated with either insufficient or ectopic mineralization (13-18). Our studies
(Chapter 2) are the first to report a role of the primary membrane transporter for
adenosine – ENT1 – in regulating soft tissue calcification in mice.
Loss of ENT1 activity would be expected to modify extracellular adenosine
levels, thus altering overall purine metabolism and signaling through adenosine receptors.
In the present study, we found that plasma adenosine concentrations are significantly
elevated in the ENT1-/- mice compared to wild-type littermates. The increased plasma
concentration of adenosine in ENT1-/- mice likely reflects extracellular accumulation of
adenosine due to the lack of uptake by cells that normally express ENT1 – one of the
primary uptake pathways for adenosine (12,19). The role of elevated extracellular
adenosine in the formation of abnormal mineral deposits in fibrocartilaginous tissues
remains to be explored, but may involve local changes in adenosine receptor signaling,
which in turn alter the expression of genes important for the regulation of
biomineralization. A recent study has linked ectopic arterial and joint calcifications with
loss of ecto-5'-nucleotidase (NT5E) function leading to decreased levels of extracellular
adenosine (15), and therefore implicates aberrant adenosine signaling in the pathogenesis
of arterial calcification.
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The gene expression data demonstrates reduced expression of genes involved in
suppressing biomineralization, such as Mgp, Enpp1, Ank, and Spp1, which could explain
the ectopic mineralization observed in the ENT1-/- mice. It is also possible that the
reduction of Alpl in the spinal tissues of ENT1-/- mice is a result of excessive mineral
present in the extracellular matrix. As a consequence, lower levels of Alpl would attempt
to decrease further mineralization.This data suggests that altered adenosine levels lead to
changes in pathways associated with mineralization signaling, specifically in the
expression

of

enzymes

regulating

PPi and

secreted

proteins

that

regulate

biomineralization (Fig. 4.1).
In conclusion, the ENT1-/- mouse may prove useful as a model for investigating
the mechanisms underlying the onset and progression of ectopic mineralization
associated with DISH and other mineralization disorders. This may lead to the
identification of risk factors, and for the evaluation of therapies for the prevention and
reversal of DISH and associated pathologies. The findings will represent a breakthrough
in our understanding of this common but as yet under-recognized disease.

4.3 Limitations of the Research and Suggestions for Future Studies
The present study was the first to report the skeletal phenotype of the ENT1-/mouse. As such, there are many future studies that can be undertaken using this model. In
Chapter 3, we performed gene expression experiments which demonstrated a downregulation of genes that regulate biomineralization (Mgp, Enpp1, Ank, Spp1, and Alpl) in
ENT1-/- mice. However, we are unable to make any conclusive statements about a
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Figure 4.1: Proposed schematic of pathways regulating biomineralization in the
ENT1-/- mouse.
In contrast to Figure 1.2, which demonstrates the pathway for physiological
biomineralization, results from these studies demonstrate disruption of these pathways in
the ENT1-/- mice. The fibrocartilage cell appears to be the cell type affected in the ENT1-/mice. Plasma adenosine levels are significantly elevated in the ENT1-/- mice compared to
the wild-type due presumably to the loss of ENT1-mediated transport. Under normal
conditions, ATP is released extracellularly and subsequently metabolized by cell-surface
enzymes. Our studies demonstrate a significant decrease in the expression of
ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1), an enzyme that
metabolizes ATP and releases inorganic pyrophosphate (PPi, which inhibits
mineralization). There is also a decrease in the expression of progressive ankylosis (Ank),
a putative transporter that mediates PPi efflux. A decrease in ENPP1 and ANK levels
would result in lower levels of the mineralization inhibitor PPi, thus allowing for
mineralization to proceed. Our studies also show a decrease in the expression of
mineralization inhibitors, matrix Gla protein (Mgp) and osteopontin (Spp1), which could
explain the ectopic mineralization observed in the ENT1-/- mice. PPi is metabolized by
alkaline phosphatase (Alpl), which produces inorganic phosphate (Pi), promoting
mineralization. Pi and Ca2+ accumulate in matrix vesicles or on extracellular matrix
components resulting in the crystallization of calcium phosphate, leading to formation of
hydroxyapatite and thus, matrix calcification. Pathogenesis appears to be associated with
the dysregulation of biomineralization pathways, and may involve both local and
systemic changes in PPi homeostasis, or PPi:Pi ratio.
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mechanism for ectopic mineralization, without any protein data. Therefore, it is necessary
to follow-up the differences we observed in gene expression with analysis of protein data
or assays of enzymatic activity. Additionally, the global differences in protein levels
between the ENT1-/- mouse and age-and-gender matched wild-type controls could also be
assessed using mass spectrometry-based proteomics.
In our studies, characterization of gene expression was performed on 6-month old
mice, at which age lesions were present in varying degrees in the spine; mineralization
was reported in 60 to 90% of the cervical spine, 30 to 60% of the thoracic spine, 0 to 30%
of the lumbar spine, and not detected in the caudal spine. Detected changes in gene
expression were restricted to IVD tissues in the presence of mineralized lesions and
therefore it is likely that the differences we observed are due to a secondary effect (the
presence of ectopic mineralization). Therefore, in order to delineate the pathway(s)
responsible for the development of hypermineralized lesions, gene expression studies
should be carried out at a younger time-point, such as 1-2 month-old mice when lesions
are first detectable by µCT. A non-biased global analysis for gene expression of ENT1-/mouse tissues (by microarray), may be necessary to identify causative factors for the
observed ectopic mineralization. Furthermore, it should be noted that although lesions are
encapsulated by the annulus fibrosus in the IVDs, gene expression studies were carried
out on the entire IVDs, which included three different tissue types. Therefore, the existing
research is technically limited as we were unable to micro-dissect the tissue of interest (in
the lab, studies are currently undergoing in order to isolate cells of the annulus fibrosus).
In addition to genetic approaches, it would be interesting to test whether longterm administration of ENT1 blockers leads to the development of DISH in wild-type
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mice. These in vivo pharmacological studies would help determine whether loss of ENT1
activity leads directly to abnormal mineralization, or whether it acts indirectly through a
developmental defect that in turn impacts biomineralization. Administration of
nitrobenzylmercaptopurine riboside (NBMPR), which is a specific inhibitor of ENT1
(20), to wild-type animals, would allow us to investigate whether animals develop
mineralization of spinal tissues similar to the phenotype observed in ENT1-/- mice.
A critical issue arises from our findings to date: ENT1 function was compromised
in all tissues and extracellular adenosine and PPi levels were systemically elevated, yet
ectopic calcification was limited to paraspinal tissues. There was no calcification in blood
vessels, cartilage and other soft connective tissue (including fibrocartilaginous structures
of the appendicular skeleton). Gene expression data does not show compensation by
other related transporters (ENT2, ENT3, and ENT4) for the loss of ENT1 in spinal tissues,
however, it is possible that in non-spinal tissues, there is an upregulation of other
transporters or the endogenous expression of related ENT transporters compensates for
the loss of ENT1. Alternatively, changes in expression of Mgp, Enpp1, Ank, Spp1, and
Alpl may not occur in non-spinal tissues, because of tissue-specific differences in
signaling. Further studies are required to better understand the tissue specificity of the
ENT1-/- phenotype.
Interestingly, the Boxer dog breed exhibits an unusually high incidence of DISH
(41% prevalence) (21), and has a 7-amino-acid deletion in a critical region of ENT1 that
may impact transport function (22). The high prevalence in a particular breed and the
relative absence of the disease in other breeds is consistent with a genetic origin.
Therefore, it is possible that ENT1 function is compromised in the Boxer dog. Tissue
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samples from Boxer dogs, as well as from humans diagnosed with DISH, will provide
information on whether there is a genetic association between mutations or single
nucleotide polymorphisms in the ENT1 gene and DISH.
Lastly, in vitro studies provide important insights into fundamental mechanisms
of biological processes. Cell and tissue culture models allow for manipulation of the
system, and could be used to investigate the mechanism that underly changes in gene
expression and excessive mineralization. To mimic hypermineralization in wild-type
cells, ENT blockers such as NBMPR, or elevated extracellular concentration of
adenosine could be used. Furthermore, in vitro experiments to attempt to “rescue”
hypermineralization in ENT1-/- cells would be informative, and can be done by
maintaining the concentration of extracellular adenosine at physiological levels, and/or
through the use of selective adenosine receptor antagonists to block adenosine signaling
via A1, A2a, A2b or A3 receptors.
The experiments outlined above will provide insight into the mechanism
underlying the development of ectopic mineralization in ENT1-/- mice and hopefully
provide a means to correlate this mechanism with biochemical and gene expression
changes in human DISH patients to determine the mechanism in humans.
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2009-030::3:
AUP Number: 2009-030
AUP Title: Purine and Pyrimidine Transport in the Cardiovasculature
Approval Date: 04/24/2009
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2009-030 has been approved.

1. This AUP number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this AUP number.
3. Purchases of animals other than through this system must be cleared through the
ACVS office.
Health certificates will be required.
REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described
in this protocol, are familiar with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated
safety components (biosafety, radiation safety, general laboratory safety) comply
with institutional safety standards and have received all necessary approvals. Please
consult directly with your institutional safety officers.
Submitted by: Kinchlea, Will D
on behalf of the Animal Use Subcommittee
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